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1. INTRODUCTION 
1.1 HERBAL MEDICINE
1,2
 
 Herbal medicine have become the remedy for most of the diseases. In 
conjunction with a healthy diet and lifestyle they target specific health goals providing 
every cell the most appropriate and optimal nourishment. These herbal supplements 
do not have any harmful side effects that might disturb physical health unlike 
synthetics. For every synthetic drug present there is an alternative herbal drug. Man in 
his everlasting search for cure of serious illnesses, at last finds his way to our 
indigenous medicine. 
 Indigenous system of medicine which is also known as traditional or folk 
medicine encompasses of medical knowledge systems that have germinated over 
generations within various societies before the era of modern medicine. Indigenous 
medicines include Herbal, Ayurveda, Siddha medicine, Unani, ancient Iranian 
medicine, Islamic Medicine, Traditional Chinese medicine, Traditional Vietnamese 
medicine, Acupuncture, Muti, Ifa, Traditional African medicine, and other medicinal 
practices all over the world.  
 The World Health Organization (WHO) defines traditional medicine as:  
"The health practices, approaches, knowledge and beliefs incorporating plant, animal 
and mineral-based medicines, spiritual therapies, manual techniques and exercises, 
applied singularly or in combination to treat, diagnose and prevent illnesses or 
maintain well-being."  
 From available literature, the use of herbs dates back 5,000 years to the 
ancient Sumerians, who described well-established medicinal uses for plants. Nature 
always stands as a golden mark to exemplify the outstanding phenomena of 
symbiosis. Nowadays people are well versed with the potency and side effects of 
synthetic drugs. Hence, there is an increasing interest in the natural product remedies 
with a basic approach towards the nature. Natural products obtained from plant, 
Introduction 
 
Department of Pharmacognosy, MMC, Chennai - 3 Page 2 
 
animal and minerals have been the backbone of the treatment of human diseases. At 
about 80 % of people in developing countries still hinge upon traditional medicine, 
based largely on species of plants and animals for their primary health care. 
Indigenous system of medicine is the need of the day.  
1.2 IMPORTANCE
3-5
 
 Ayurveda is a traditional system of medicine using a wide range of modalities 
to create health and wellbeing. The main aspire of Ayurveda health care is to restore 
the physical mental and emotional balance in patients, thus improving the health, 
preventing disease and to treat any current illness. The number of patients looking for 
alternate and herbal therapy is growing exponentially. Thus the herbal medicines are 
now in great demand in the developing world for primary healthcare not only for its 
inexpensiveness but also for better cultural acceptability; better compatibility with the 
human body and minimal side effects. 
  Herbal medicine is still the mainstay of about 75 – 80% of the world 
population for primary healthcare mainly in the developing countries. However 
among the estimated 250,000 – 400,000 of plant species, only about 6% have been 
studied for biological activity, and about 15% have been investigated based on its 
phytochemicals. Therefore it seems necessary to evaluate the herbs properly. 
 
 The first reason for the use of herbals is that it is part of the culture and belief 
of some people for maintenance of health or to treat certain ailments. The second 
reason for the increased use of herbals is the relatively cheaper cost of herbal products 
and hence affordability to the lower income group. The third reason is that the public 
has the impression of herbals being natural and that anything natural is safe. There is 
also this notion that herbal products do not contain chemicals and only those 
chemicals found in modern medicines, are linked to toxicity, and hence are more 
harmful. 
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1.3 FORMULATION OF HERBAL PRODUCTS
6
 
 An herbal ―formula‖ consists of a selective combination of individual herbal 
ingredients that are formulated for a specific ailment or group of disease-conditions. 
When herbs are combined together, they become more potent and effective within the 
body than single herb due to their activating or catalyzing influence upon one another. 
These combinations acts as powerful catalysts in order to activate over own individual 
healing energies (or vital force) which permeate the entire organism and reside in 
each and every cell in our bodies. 
1.3.1 Advantages of Herbal Formulations:  
 There are a number of advantages associated with using herbal medicines as 
opposed to allopathic products. Examples include the following:  
• Reduced risk of side effects: Most herbal medicines are well tolerated by the 
patient, with fewer unintended consequences than pharmaceutical drugs. Herbs 
typically have fewer side effects than traditional medicine, and may be safer to use 
over time. 
WHO Guidelines for Standardization of Herbal Formulation
7,8
 
 Standardization is an important aspect for maintaining and assessing the 
quality and safety of the polyherbal formulation as these are combinations of more 
than one herb to attain the desire therapeutic effect. Standardization minimizes batch 
to batch variation, assures safety, efficacy, quality and acceptability of the polyherbal 
formulations. Standardisation involves:   
 Quality control of crude drugs material, plant preparations and finished 
products.  
 Stability assessment and shelf life.  
 Safety assessment, documentation of safety based on experience or 
toxicological studies.  
 Assessment of efficacy by ethnomedical informations and biological activity 
evaluations 
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1.3.2. Capsule formulated with herbs 
6,9
 
 
                                   Figure :1 Capsule formulated with herbs  
 
 Herbal products can be formulated in the form of Capsules, Tablets, Syrups, 
Lehiyas, Tailas, Bhasmas, Powders etc. The most versatile form is the capsule form 
that provides conventional drug delivery for controlling absorption, enhancing 
bioavailability and dosage accuracy. It is easier to consume a formulated capsule 
containing active ingredients than to swallow the herbs as such.  
 The word ―capsule‖ in the English language is derived from the Latin word 
―Capsula‖, which means a small box or container in more recent times, capsule has 
been used primarily to describe a solid oral dosage form, which consists of a 
container,usually made of gelatin filled with a medicinal substance. There are many 
forms of capsules and they can be divided into two main categories, which in current 
English usage are described by the adjectives ―hard‖ and ―soft‖. The ―hard capsule‖ 
consists of two separate parts, each semi-closed cylinder in shape. One part the ―cap‖ 
has a slightly larger diameter than the other, which is called the ―body‖ and is longer 
the cap fits closely over the body to form a sealed unit. 
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1.4. Diabetes mellitus
10-13 
 As per WHO, Diabetes Mellitus is defined as heterogenous metabolic 
disorder characterised by common feature of chronic hyperglycemia with 
disturbance of carbohydrate, protein and fat metabolism. 
Types of diabetes 
 
 Type - I diabetes (insulin dependent diabetes mellitus) 
 Type - II diabetes (formerly, non-insulin dependent diabetes mellitus) 
 Gestational diabetes (first recognition during pregnancy) 
 Diabetes due to other causes (genetic defects or medication) 
Type 1 diabetes (formerly known as insulin-dependent) in which the pancreas fails 
to produce the insulin which is essential for survival. This form develops most 
frequently in children and adolescents, but is being increasingly noted later in life. 
 
Type 2 diabetes (formerly named non-insulin-dependent) which results from the 
body's inability to respond properly to the action of insulin produced by the 
pancreas. Type 2 diabetes is much more common and accounts for around 90% of 
all diabetes cases worldwide. It occurs most frequently in adults, but is being noted 
increasingly in adolescents as well. 
 Certain genetic markers have been shown to increase the risk of developing 
Type 1 diabetes. Type 2 diabetes is strongly familial, but it is only recently that 
some genes have been consistently associated with increased risk for Type 2 
diabetes in certain populations. Both types of diabetes are complex diseases caused 
by mutations in more than one gene, as well as by environmental factors. 
GESTATIONAL DIABETES 
 Diabetes that's triggered by pregnancy is called gestational diabetes 
(pregnancy, to some degree, leads to insulin resistance). It is often diagnosed in 
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middle or late pregnancy. Because high blood sugar levels in a mother are 
circulated through the placenta to the baby, gestational diabetes must be controlled 
to protect the baby's growth and development. 
 The rate of gestational diabetes is between 2% to 10% of pregnancies. 
Gestational diabetes usually resolves itself after pregnancy. Up to 10% of women 
with gestational diabetes develop type 2 diabetes. It can occur anywhere from a 
few weeks after delivery to months or years later. 
 Diabetes in pregnancy[gestational diabetes] may give rise to several 
adverse outcomes, including congenital malformations, increased birth weight and 
an elevated risk of perinatal mortality. Strict metabolic control may reduce these 
risks to the level of those of non-diabetic expectant mothers. 
  
Symptoms 
  
The symptoms of diabetes may be pronounced, subdued, or even absent. 
 In Type 1 diabetes, the classic symptoms are excessive secretion of urine 
(polyuria), thirst (polydipsia), weight loss and tiredness. 
 These symptoms may be less marked in Type 2 diabetes. In this form, it can 
also happen that no early symptoms appear and the disease is only 
diagnosed several years after its onset, when complications are already 
present. 
Epidemiology of diabetes 
 The incidence of diabetic is growing rapidly in United States and worldwide. 
Globally as of 2010, an estimated 285 million people had diabetes, with type II 
making up about 90% of the cases. In 2013, according to International Diabetes 
Federation an estimated 381 million people had diabetes, its prevalence is increasing 
rapidly. It is estimated that more than 250 million people worldwide are afflicted with 
diabetes and the prevalence is expected to exceed 350 million by the year 2030. 
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PATHOPHYSIOLOGY 
 
Pancreas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          Figure : 2  Human Pancreas 
 
Figure: 3 Langerhans 
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The hormones play an important role in regulating the metabolic activities of the  
body, particularly the hameostasis of blood glucose. The pancreas is both an 
endocrine and exocrine gland, in which endocrine produces the peptide hormone 
insulin, glucagon and somatostatin and exocrine gland produces digestive enzymes 
The peptide hormones are secreted from cells located in the islet of langerhans 
 (β cells produce insulin, alpha cells produces glucagon and δ cells produce 
somatostatin). 
 
Insulin 
 
 Insulin was discovered in 1921 by Banting and best who demonstrated the 
hypoglycaemic action of an extract of pancreas. In 1922 an extract containing insulin 
was first used on a 14 year old boy suffering from severe diabetes mellitus with 
excellent response. Insulin was then purified in a few years. 
Insulin Structure 
 Insulin is composed of two chains of amino acids named chain A (21 amino 
acids) and chain B (30 amino acids) that are linked together by two disulfide bridges. 
There is a 3rd disulfide bridge within the A chain that links the 6th and 11th residues 
of the A chain together. 
 In most species, the length and amino acid compositions of chains A and B are 
similar, and the positions of the three disulfide bonds are highly conserved. For this 
reason, pig insulin can be used to replace deficient human insulin levels in diabetes 
patients. Today, porcine insulin has largely been replaced by the mass production of 
human proinsulin by bacteria (recombinant insulin). 
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Insulin secretion  
Figure:4 Secretion of Insulin in β cells 
 The insulin-making cells of the body are called beta cells, and they are found 
in the pancreas gland. These cells clump together to form the "islets of Langerhans", 
named for the German medical student who described them.  
Rising levels of glucose inside the pancreatic beta cells trigger the release of insulin: 
 
Introduction 
 
Department of Pharmacognosy, MMC, Chennai - 3 Page 10 
 
 
1. Glucose is transported into the beta cell by type 2 glucose transporters 
(GLUT2). Once inside, the first step in glucose metabolism is the 
phosphorylation of glucose to produce glucose-6-phosphate. This step is 
catalyzed by glucokinase—it is the rate-limiting step in glycolysis, and it 
effectively traps glucose inside the cell. 
2. As glucose metabolism proceeds, ATP is produced in the mitochondria. 
3. The increase in the ATP:ADP ratio closes ATP-gated potassium channels in 
the beta cell membrane. Positively charged potassium ions (K
+
) are now 
prevented from leaving the beta cell. 
4. The rise in positive charge inside the beta cell causes depolarization. 
5. Voltage-gated calcium channels open, allowing calcium ions (Ca2+) to flood 
into the cell. 
6. The increase in intracellular calcium concentration triggers the secretion of 
insulin via exocytosis. 
 There are two phases of insulin release in response to a rise in glucose. The 
first is an immediate release of insulin. This is attributable to the release of preformed 
insulin, which is stored in secretory granules. After a short delay, there is a second, 
more prolonged release of newly synthesized insulin. 
 Once released, insulin is active for a only a brief time before it is degraded by 
enzymes. Insulinase found in the liver and kidneys breaks down insulin circulating in 
the plasma, and as a result, insulin has a half-life of only about 6 minutes. This short 
duration of action allows rapid changes in the circulating levels of insulin. 
Insulin Receptor 
 The net effect of insulin binding is to trigger a cascade of phosphorylation and 
dephosphorylation reactions. These actions are terminated by dephosphorylation of 
the insulin receptor. 
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 Similar to the receptors for other polypeptide hormones, the receptor for 
insulin is embedded in the plasma membrane and is composed of a pair of alpha 
subunits and a pair of beta subunits. The alpha subunits are extracellular and contain 
the insulin-binding site. The beta subunits span the membrane and contain the enzyme 
tyrosine kinase. Kinases are a group of enzymes that phosphorylate proteins (the 
reverse reaction is catalyzed by a group of enzymes called phosphatases). 
  
 
Figure: 5 The insulin receptor 
 The insulin receptor is a tyrosine kinase receptor and is composed of a pair of 
alpha subunits and a pair of beta subunits. Insulin binds to the alpha subunits and 
induces a conformational change that is transmitted to the beta subunits that 
autophosphorylate and initiate a cascade of phosphorylation and dephosphorylation 
reactions.  
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 Insulin binding to the alpha subunits induces a conformational change that is 
transmitted to the beta subunits and causes them to phosphorylate themselves 
(autophosphorylation). A specific tyrosine of each beta subunit is phosphorylated 
along with other target proteins, such as insulin receptor substrate (IRS). As these and 
other proteins inside the cell are phosphorylated, this in turn alters their activity, 
bringing about the wide biological effects of insulin. 
Insulin Action 
 The binding of insulin results in a wide range of actions that take place over 
different periods of time. Almost immediately, insulin promotes the uptake of glucose 
into many tissues that express GLUT4 glucose transporters, such as skeletal muscle 
and fat. Insulin increases the the activity of these transporters and increases their 
numbers by stimulating their recruitment from an intracellular pool to the cell surface. 
Not all tissues require insulin for glucose uptake. Tissues such as liver cells, red blood 
cells, the gut mucosa, the kidneys, and cells of the nervous system use a glucose 
transporter that is not insulin dependent. 
Over minutes to hours, insulin alters the activity of various enzymes as a result of 
changes in their phosphorylation status. 
Over a period of days, insulin increases the amounts of many metabolic enzymes. 
These reflect an increase in gene transcription, mRNA, and enzyme synthesis. 
After a Meal—the Role of Insulin 
The rise in blood glucose following a meal is detected by the pancreatic beta cells, 
which respond by releasing insulin. Insulin increases the uptake and use of glucose by 
tissues such as skeletal muscle and fat cells. This rise in glucose also inhibits the 
release of glucagon, inhibiting the production of glucose from other sources, e.g., 
glycogen break down.  
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Figure: 6 Changes in key hormones after a meal 
 
Changes in blood levels of glucose, insulin, and glucagon after a carbohyrate-rich 
meal (ingested at time 0 minutes 
1. Use Glucose 
 Once inside the cell, some of the glucose is used immediately via glycolysis. 
This is a central pathway of carbohydrate metabolism because it occurs in all cells in 
the body, and because all sugars can be converted into glucose and enter this pathway. 
During the well-fed state, the high levels of insulin and low levels of glucagon 
Introduction 
 
Department of Pharmacognosy, MMC, Chennai - 3 Page 14 
 
stimulate glycolysis, which releases energy and produces carbohydrate intermediates 
that can be used in other metabolic pathways. 
2. Make Glycogen 
 Any glucose that is not used immediately is taken up by the liver and muscle 
where it can be converted into glycogen (glycogenesis). Insulin stimulates 
glycogenesis in the liver by: 
 stimulating hepatic glycogen synthetase (the enzyme that catalyzes glycogen 
synthesis in the liver) 
 inhibiting hepatic glycogen phosphorylase (the enzyme that catalyzes glycogen 
breakdown in the liver) 
 inhibiting glucose synthesis from other sources (inhibits gluconeogenesis) 
 Insulin also encourages glycogen formation in muscle, but by a different 
method. Here it increases the number of glucose transporters (GLUT4) on the cell 
surface. This leads to a rapid uptake of glucose that is converted into muscle 
glycogen. 
3. Make Fat 
 When glycogen stores are fully replenished, excess glucose is converted into 
fat in a process called lipogenesis. Glucose is converted into fatty acids that are stored 
as triglycerides (three fatty acid molecules attached to one glycerol molecule) for 
storage. Insulin promotes lipogenesis by: 
 increasing the number of glucose transporters (GLUT4) expressed on the 
surface of the fat cell, causing a rapid uptake of glucose 
 increasing lipoprotein lipase activity, which frees up more fatty acids for 
triglyceride synthesis 
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 In addition to promoting fat synthesis, insulin also inhibits fat breakdown by 
inhibiting hormone-sensitive lipase (an enzyme that breaks down fat stores). As a 
result, there are lower levels of fatty acids in the blood stream. 
 Insulin also has an anabolic effect on protein metabolism. It stimulates the 
entry of amino acids into cells and stimulates protein production from amino acids. 
Fasting—the Role of Glucagon 
 Fasting is defined as more than eight hours without food. The resulting fall in 
blood sugar levels inhibits insulin secretion and stimulates glucagon release. 
Glucagon opposes many actions of insulin. Most importantly, glucagon raises blood 
sugar levels by stimulating the mobilization of glycogen stores in the liver, providing 
a rapid burst of glucose. In 10–18 hours, the glycogen stores are depleted, and if 
fasting continues, glucagon continues to stimulate glucose production by favouring 
the hepatic uptake of amino acids, the carbon skeletons of which are used to make 
glucose. 
 In addition to low blood glucose levels, many other stimuli stimulate glucagon 
release including eating a protein-rich meal (the presence of amino acids in the 
stomach stimulates the release of both insulin and glucagon, glucagon prevents 
hypoglycemia that could result from unopposed insulin) and stress (the body 
anticipates an increased glucose demand in times of stress). 
 “Starvation in the Midst of Plenty” 
 Diabetes is often referred to as ―starvation in the midst of plenty‖ because the 
intracellular levels of glucose are low, although the extracellular levels may be 
extremely high. 
 As in starvation, type 1 diabetics use non-glucose sources of energy, such as 
fatty acids and ketone bodies, in their peripheral tissues. But in contrast to the 
starvation state, the production of ketone bodies can spiral out of control. Because the 
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ketones are weak acids, they acidify the blood. The result is the metabolic state of 
diabetic ketoacidosis (DKA). Hyperglycemia and ketoacidosis are the hallmark of 
type 1 diabetes. 
 
 
Figure: 7 Metabolic changes in Ketoacidosis 
 
 Hyperglycemia is caused by the increased production of glucose by the liver 
(driven by glucagon) and the decreased use of glucose of insulin by peripheral tissues 
(because of the lack of insulin 
 Hypertriglyceridemia is also seen in DKA. The liver combines triglycerol with 
protein to form very low density lipoprotein (VLDL). It then releases VLDL into the 
blood. In diabetics, the enzyme that normally degrades lipoproteins (lipoprotein 
lipase) is inhibited by the low level of insulin and the high level of glucagon. As a 
result, the levels of VLDL and chylomicrons (made from lipid from the diet) are high 
in DKA. 
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Prevalence 
 Recently compiled data show that approximately 150 million people have 
diabetes mellitus worldwide, and that this number may well double by the 
year 2025. Much of this increase will occur in developing countries and 
will be due to population growth, ageing, unhealthy diets, obesity and 
sedentary lifestyles. 
 By 2025, while most people with diabetes in developed countries will be 
aged 65 years or more, in developing countries most will be in the 45-64 
year age bracket and affected in their most productive years. 
Diagnosis 
 WHO has published recommendations on diagnostic values for blood 
glucose concentration. The diagnostic level of fasting blood glucose 
concentration was last modified in 1999. 
Treatment 
 The mainstay of non-pharmacological diabetes treatment is diet and physical 
activity. 
 About 40% of diabetes sufferers require oral agents for satisfactory blood 
glucose control, and some 40% need insulin injections. This hormone was 
isolated by Frederic Banting and Charles Best in 1921 in Canada. It 
revolutionized the treatment of diabetes and prevention of its complications, 
transforming Type 1 diabetes from a fatal disease to one in which long-term 
survival became achievable. 
 People with Type 1 diabetes are usually totally dependent on insulin injections 
for survival. Such people require daily administration of insulin. The majority 
of people suffering from diabetes have the Type 2 form. Although they do not 
depend on insulin for survival, about one third of sufferers needs insulin for 
reducing their blood glucose levels. 
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Complications associated with diabetes mellitus 
 Diabetic retinopathy is a leading cause of blindness and visual disability. 
Diabetes mellitus is associated with damage to the small blood vessels in 
the retina, resulting in loss of vision. Findings, consistent from study to 
study, make it possible to suggest that, after 15 years of diabetes, 
approximately 2% of people become blind, while about 10% develop 
severe visual handicap. Loss of vision due to certain types of glaucoma and 
cataract may also be more common in people with diabetes than in those 
without the disease. 
 Good metabolic control can delay the onset and progression of diabetic 
retinopathy. Loss of vision and blindness in persons with diabetes can be 
prevented by early detection and treatment of vision-threatening 
retinopathy: regular eye examinations and timely intervention with laser 
treatment, or through surgery in cases of advanced retinopathy. There is 
evidence that, even in developed countries, a large proportion of those in 
need is not receiving such care due to lack of public and professional 
awareness, as well as an absence of treatment facilities. In developing 
countries, in many of which diabetes is now common, such care is 
inaccessible to the majority of the population. 
 Diabetes is among the leading causes of kidney failure, but its frequency 
varies between populations and is also related to the severity and duration 
of the disease. Several measures to slow down the progress of renal damage 
have been identified. They include control of high blood glucose, control of 
high blood pressure, intervention with medication in the early stage of 
kidney damage, and restriction of dietary protein. Screening and early 
detection of diabetic kidney diseae are an important means of prevention. 
 Heart disease accounts for approximately 50% of all deaths among people 
with diabetes in industrialized countries. Risk factors for heart disease in 
people with diabetes include smoking, high blood pressure, high serum 
cholesterol and obesity. Diabetes negates the protection from heart disease 
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which pre-menopausal women without diabetes experience. Recognition 
and management of these conditions may delay or prevent heart disease in 
people with diabetes. 
 Diabetic neuropathy is probably the most common complication of 
diabetes. Studies suggest that up to 50% of people with diabetes are 
affected to some degree. Major risk factors of this condition are the level 
and duration of elevated blood glucose. Neuropathy can lead to sensory loss 
and damage to the limbs. It is also a major cause of impotence in diabetic 
men. 
 Diabetic foot disease, due to changes in blood vessels and nerves, often 
leads to ulceration and subsequent limb amputation. It is one of the most 
costly complications of diabetes, especially in communities with inadequate 
footwear. It results from both vascular and neurological disease processes. 
Diabetes is the most common cause of non-traumatic amputation of the 
lower limb, which may be prevented by regular inspection and good care of 
the foot. 
Prevention 
 Large, population-based studies in China, Finland and USA have recently 
demonstrated the feasibility of preventing, or delaying, the onset of diabetes in 
overweight subjects with mild glucose intolerance (IGT). The studies suggest that 
even moderate reduction in weight and only half an hour of walking each day 
reduced the incidence of diabetes by more than one half. 
 Diabetes is a serious and costly disease which is becoming increasingly 
common, especially in developing countries and disadvantaged minorities. 
However, there are ways of preventing it and/or controlling its progress. Public and 
professional awareness of the risk factors for, and symptoms of diabetes are an 
important step towards its prevention and control. 
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1.5.  HERBAL DRUGS  FOR DIABETES MELLITUS
14-16
  
 In the Ayurvedic system of medicine, as mentioned in ancient Indian books 
like Charak Samhita, Mahdhav Nidan and Astang Sanghra, there are about 600 plants, 
which are stated to have antidiabetic property. Wide arrays of plant derived active 
principles representing numerous phytochemicals have demonstrated consistent 
hypoglycemic activity and their possible use in the treatment of diabetes mellitus.  
 Indian plants which are most effective and commonly studied in relation to 
diabetes are namely Allium cepa, Allium sativum, Aloevera, Berberis aristata, 
Cajanus cajan, Coccinia indica, Caesalpinia bonducella, Cyperus rotundus,  Ficus 
bengalenesis, Gymnema sylvestre, Momordica charantia, Ocimum sanctum, 
Pterocarpus marsupium, Swertia chirayita, Syzigium cumini Terminalia belerica, 
Terminalia chebula, Tinospora cordifolia, Trigonella foenum, Phyllanthus emblica, 
Annona squamosa etc. 
 Herbal medicines have been used to cure diabetes as anti-diabetic regimens 
alone or in compound. Therefore, research is still on the nascent stage to find more 
effective and safer hypoglycemic agents. For a long time, several medicinal plants 
have been used for the treatment of diabetes in the form of compound drugs. 
Moreover, after the reference made by researchers on diabetes mellitus, investigations 
on the hypoglycemic activity of compound drugs of medicinal plants have been more  
important. 
 Polyherbal formulations may enhance the pharmacological activity and reduce 
the concentrations of single herbs, thereby reducing adverse effects. Plant formulation 
and combined extracts of plants have been used as a drug rather than individual.  
 Exploring an effective drug either single or in combination against diabetes is 
challenging still. Hence we planned to develop antidiabetic  polyherbal formulation in 
the form of capsule containing ethanolic extracts of  Berberis aristata (dried Stem), 
Terminalia chebula (pericarp of matured fruit), Emblica officinalis (pericarp of dried 
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matured fruit),Terminalia belerica (pericarp of dried ripe fruit) and  Cyperus rotundus 
(dried rhizome). Ethno medically, the preparation was prescribed in the form of 
Decoction
17
. This traditional dosage form has several disadvantages like shelf life of 
decoction as per literature is three hours
18
 making it prone to physical, chemical and 
microbiological instability and it is also bitter in taste. To overcome these problems 
we planned to prepare ethanolic extract and followed by development of this 
preparation in to a suitable drug delivery system in the form of capsule was sought to 
be of appropriate pharmacopoeial quality and would have similar release of the 
actives as that of the traditional dosage form. 
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3. PLANT PROFILE 
Berberis Aristata DC.
35,36 
  
Fig:8 whole plant of Berberis Aristata DC. 
Synonym   : Berberis Tinctoria, Berberis chitia Ham 
Family   : Berberidaceae 
Common name  :Tree turmeric 
Parts used   :Dried stem 
Vernacular Names 
Sanskrit   :Daruharidra 
English   :Tree turmeric 
Hindi    : Daruhallada 
Tamil    :Maramanjal 
PLANT TAXANOMY 
Kingdom   :Plantae 
Order    : Angiosperms 
Family   : Berberidaceae 
Genus    : Berberis 
Species   : Berberis aristata 
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Fig:9 Dried stem of  Berberis aristata 
Distribution   : Himalayas, Nepal. 
Description: 
Spinous shrubs; axillary thorns with fragrant greenish flowers in racemes and dark 
red-brown berries. 
Phytoconstituents: 
Plant contains alkaloids: Berberine, Oxycantine, Berbamine, Palmatine, Jatrorrhisine, 
columbamine, Berberrubine, Hydrastine, Gum, Starch. 
Ethno- Medicinal uses: 
Fruits :Haemorrhoids, laxative 
Root : Opthalmia, antipyretic, laxative,tonic, malaria fever, rheumatism, diarrhoea,
 skin diseases. 
Stem : Diarrhoea, diabetes, ulcers, opthalmic diseases. 
Dose : 5-10 ml of the drug in Deoction form. 
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Terminalia Chebula Retz.
36,37
 
  
 
                                  Fig:10 whole plant of Terminalia Chebula   
 
Family   : Combretaceae 
Common name  : Myrobalan 
Parts used   : Pericarp of mature fruits 
Vernacular Names 
Sanskrit   : Abhaya, Haritaki 
English   : Black Myrobalan 
Hindi    : Harra, Harad 
Tamil    : Kadukkai 
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PLANT TAXANOMY 
Kingdom   : Plantae 
Order    : Myrtales 
Family   : Combretaceae 
Genus    : Terminalia 
Species   : Terminalia chebula 
                 
                                    Fig:11  Terminalia chebula fruit 
Distribution   : Throughout the greater part of India 
Description: 
Deciduous trees, Leaves ovate or elliptic. Flowers yellow or creamy white, in spikes. 
Fruits 5-ridged. 
Phytoconstituents: 
Fruits contain- Tannic acid, gallic acid, Chebulinic acid, mucilage,glycoside 
(Anthroquinone), Carbohydrates, aminoacids,phosphoric acid, succinic acid. 
Ethno- Medicinal uses: 
Fruits : Diabetes, dysentry, diarrhoea, gout, malaria, sore throat, pneumonia,  
  Anaemia, typhoid  
Bark : Ezema 
Dose : 3-6g of the drug in powder form 
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Emblica officinalis Gaertn.
38,39 
 
                 Fig 12:Whole plant of Emblica officinalis 
Synonym   : Phyllanthus emblica L.  
Family   : Euphorbiaceae 
Common name  : Amla 
Parts used   : Pericarp of dried matured fruits 
Vernacular Names 
Sanskrit   : Amalaka, Dhhatriphala 
English   : Emblic myrobalan 
Hindi    : Amvala 
Tamil    : Nelli, Nellikkai 
PLANT TAXANOMY 
Kingdom   : Plantae 
Order    : Malpighiales 
Family   : Euphorbiaceae 
Genus    : Phyllanthus 
Species   : Phyllanthus emblica 
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                                   Fig 13: Phyllanthus emblica fruit 
Distribution : Throughout India 
Description: 
Large, deciduous trees, with distichous, linear-oblong leaves.  Flowers greenish-
yellow, in fascicles on leafless branches.  Fruits globose, fleshy; Seeds bony. 
Phytoconstituents: 
Fruits contain protein, fats, fibres, carbohydrates, vitamin c, Nicotinic acid, Tannins. 
After drying fruits contain Gallic acid, Ellagic acid, Flavin & glucose. Seed contains 
Linoleic acid, Linolenic acid, Oleic acid. 
Ethno- Medicinal uses: 
Fruits : Diabetes, dysentry, diarrhoea, Anaemia, bronchitis, leprosy, leucorrhoea, 
inflammation of the eyes, malaria, scurvy constipation   
Bark : Diarrhoea, gonorrhoea, jaundice. 
Leaf : conjunctivitis, diarrhoea, inflammation. 
Dose : 3-6g of the drug in powder form 
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Terminalia belerica ( Gaertn.)Roxb.
40 
 
                                  Fig 14: Whole plant of Terminalia belerica 
Family   : Combretaceae 
Common name  : Beleric myrobalan 
Parts used   : Pericarp of dried ripe fruit 
Vernacular Names 
Sanskrit   : Bibhitaka,Aksha,Vibhita 
English   : Beleric myrobalan 
Hindi    : Bahera 
Tamil    : Thantrikkai 
PLANT TAXANOMY 
Kingdom   : Plantae 
Order    : Myrtales 
Family   : Combretaceae 
Genus    : Terminalia 
Species   : Terminalia belerica 
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                            Fig 15: Terminalia belerica fruit 
Distribution : Throughout the forest of India 
Description: 
Deciduous trees, with broadly ovate leaves clustered at the end of branches. Flowers 
yellow or creamy white, in spikes. Fruits ellipsoid, 5-ridged. 
Phytoconstituents: 
Fruits contains β-Sitosterol, gallic acid, ellagic acid, chebulagic acid, Galloyl, 
gluocse, many free sugars, manitol, galactose, rhamnose, glucoside. 
Ethno- Medicinal uses: 
Fruits : Diabetes, diarrhoea, Anaemia,  asthma, bronchitis, leprosy, cough, cardiac 
diseases, liver problems,headache, constipation, skin diseases, inflammation , malaria, 
sore throat.  
Bark : Anaemia, Leucoderma,cold 
Seed oil: Swelling, skin diseases. 
Dose : 3-6g of the drug in powder form 
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Cyperus rotundus L.
41,42 
 
                                  Fig16 :Whole plant of Cyperus rotundus 
Synonym   : Cyperus hexastachys Rottb. 
Family   : Cyperaceae 
Common name  : Nut Grass 
Parts used   : Dried rhizome 
Vernacular Names 
Sanskrit   : Musta,Mustaka 
English   : Nut Grass 
Hindi    : Motha, Nagarmotha 
Tamil    : Korai, Korai-Kizhangu 
PLANT TAXANOMY 
Kingdom   :  Plantae 
Order    : Polaes 
Family   :Cyperaceae 
Genus    : Cyperus 
Species   : Cyperus rotundus 
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                                Fig 17:Rhizomes of Cyperus rotundus 
Distribution : Throughout the forest of India 
Description: 
Sedges, with slender stolons terminated by ellipsoid or globose-ovoid tubers. Leaves 
not exceeding the clum. Spikes born in terminal corymbs; spikelets dusty brown, 8 to 
28 flowered, rachilla winged. Achnes triqutous, brown. 
Phytoconstituents: 
Rhizome contains Penene, cineol, Linoleic acid, oleic acid, Myristic acid, stearic, 
glycerol, glycoside cyperene, cyperenone, sugars,gum, carbohydrates. 
Ethno- Medicinal uses: 
Acrid, anthelmentic, anti- inflammatory, diabetes, expectorant, jaundice, leprosy, 
scabies, dysmenorrhoea, dyspepsia, flatulence, ulcer, stomach pain. 
Dose : 3-6g of the drug in powder form 
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4. AIM AND OBJECTIVE 
AIM  
 The aim of the present work is to develop a polyherbal anti- diabetic capsules 
from the selected plant material and evaluate the same. 
 
OBJECTIVE 
 
 To perform the raw material analysis. 
 
 To extract the plant material by continuous Hot Percolation method using 
ethanol as solvent. 
 
 To formulate and evaluate  polyherbal capsule. 
 
 To evaluate the antidiabetic activity by In vitro and In vivo models. 
. 
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5. PLAN OF WORK 
 
I. Collection and Authentication 
II. Processing of raw materials 
III. RAW MATERIALS STANDARDIZATION 
 Organoleptic Evaluation 
 Microscopical evaluation  
 Physico-chemical Evaluation.  
 Loss on Drying 
 Determination of Ash values 
 Total ash value 
 Acid insoluble ash value 
 Water soluble ash value 
 Sulphated ash value 
 Determination of Extractive values 
 Water soluble extractive value 
 Alcohol soluble extractive value 
 Ether soluble extractive value 
 Quantitative Estimation of Heavy metals and Inorganic elements 
 Microbial load 
 
IV. PHYTOCHEMICAL STUDIES 
 Preliminary phytochemical screening of powder and extracts  
 Preparation of Extract 
 Fluorescence analysis of raw materials 
 Thin Layer Chromatography 
 HPTLC - Finger print analysis 
 
V. DEVELOPMENT OF FORMULATION  
 Pre formulation studies 
 Selection of excipient 
PLAN OF WORK 
 
Dept. of Pharmacognosy, COP, MMC, Chennai-03. Page 36 
 
 Flow property measurement  
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner’s ratio 
 Angle of repose 
 Trial batches (I, II, III, IV) (Selection of optimized batches) 
 Formulation of capsules 
 
VI. STANDARDIZATION OF POLYHERBAL CAPSULES 
 Description 
 pH 
 Uniformity of weight 
 Disintegration time 
 Ash value  
 Extractive value 
 Quantitative estimation of Phytoconstituents 
 Quantitative Estimation of Heavy metals and Inorganic elements 
 Microbial load 
 
VII. PHARMACOLOGICAL STUDIES 
 In vitro studies:  
 α-amylase inhibitory assay. 
 In vivo Streptozotocin induced diabetes in rats 
 Blood glucose level 
 Lipid profile  
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6. MATERIALS AND METHODS 
  MATERIALS  
 Polyherbal antidiabetic formulation consists of five herbs  viz., Berberis 
aristata (dried Stem), Terminalia chebula (pericarp of matured fruit), Emblica 
officinalis (pericarp of dried matured fruit),Terminalia belerica (pericarp of dried ripe 
fruit) and Cyperus rotundus (dried rhizome). 
Table 1. MATERIALS SELECTED FOR FORMULATION  
S.no Name of the materials Manufacturer /Supplier Use in formulation 
1 Berberis aristata  
M/S. K.Ramaswamy Chetty 
drug dealer,Chennai-03 Active ingredient 
2 Terminalia chebula 
M/S. K.Ramaswamy Chetty 
drug dealer,Chennai-03 Active ingredient 
3 Emblica officinalis 
M/S. K.Ramaswamy Chetty 
drug dealer,Chennai-03 Active ingredient 
4 Terminalia belerica 
M/S. K.Ramaswamy Chetty 
drug dealer,Chennai-03 Active ingredient 
5 Cyperus rotundus 
M/S. K.Ramaswamy Chetty 
drug dealer,Chennai-03 Active ingredient 
6 Lactose 
Indian research products 
limited Diluent 
7 Micro crystalline cellulose Pharma French Ltd. Diluent/Disintegrant 
8 Magnesium carbonate Kniss Laboratories Adsorbant 
9 Starch  Alkimas pvt Ltd,Chennai Binder/Disintegrant 
10 Sodium methyl paraben 
Global medicines Ltd, 
Gujarat Preservative 
11 Bronopol 
Global medicines Ltd, 
Gujarat Preservative 
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6.1. COLLECTION AND AUTHENTICATION 
 Herbs used for formulation were procured from the authentic suppliers and 
further authenticated by Dr. K.N. Sunil Kumar  R.O. and HOD Pharmacognosy, 
Central Siddha Research Institute, Government of  India, Arumbakkam, Chennai-106.  
6.2. PROCESSING OF RAW MATERIALS 
 The procured plant materials were cleaned thoroughly. They were then dried 
under shade for a week or so. Once they were completely dried, they were ground into 
coarse powder and stored in air tight containers and preserved for the further 
processing. 
6.3. STANDARDISATION OF RAW MATERIALS
43 
 
Shade dried powdered plant materials of the plants, Berberis aristata (dried 
Stem), Terminalia chebula (pericarp of matured fruit), Emblica officinalis (pericarp of 
dried matured fruit),Terminalia belerica (pericarp of dried ripe fruit) and Cyperus 
rotundus (dried rhizome)  used for the standardization of raw materials. 
6.3.1. ORGANOLEPTIC EVALUATION 
Organoleptic evaluation defines the majority of information on the identity, 
purity of the material which are of primary importance for the establishment of degree 
of quality done by sensory organs for the evaluation of drugs colour, odour, taste and 
specific characters. 
In this study the following organoleptic characters like physical appearance, 
taste and odour of plant materials were evaluated and confirmed with reference 
samples. 
6.3.2 MICROSCOPICAL EVALUATION 
POWDER MICROSCOPY
44 
 Powder characters show the detailed examination of a drug which is mainly 
used to identify the organised drugs by their known structural characters. The 
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structural characters are distinguished with various reagents and stains. The powder 
characters of the crude drug powder were studied using microscope. 
Methodology 
 A pinch of the powdered sample was mounted on a microscopic slide with a 
drop of phloroglucinol and conc. HCl. Characters were observed under microscope. 
6.3.3 PHYSICO CHEMICAL EVALUATION 
Out of the numerous practical applications of pharmacognosy, the great 
importance for the pharmaceutical industry is in the evaluation of the crude drugs. 
The evaluation of these parameters shows the clear idea about the specific 
characteristic of crude drugs. It is virtually impossible to avoid some naturally 
occurring inorganic and organic contaminants while collection from soil. The 
procedures normally adopted to get the purity and standards of a crude drugs which 
affects the product quality which include the determination of various parameters.. 
A. LOSS ON DRYING 
The test for loss on drying determines both water and volatile matter in the 
crude drug. The loss on drying test is important when the herbal substances are 
known to be hygroscopic. An excess of water in herbal materials will encourage 
microbial growth, presence of fungi, insects and deterioration. In modern 
pharmaceutical technology, the water content provides information concerning the 
shelf life and the quality of the drugs. Loss on drying is the loss of mass expressed as 
% w/w. 
 About 10 g of drug was weighed in a tarred flat weighing bottle previously 
dried and dried at 105
o
C for 5 hours cooled in a suitable dessicator and weighed. The 
drying was continued and weighed to a constant weight at one hour interval.  
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B. DETERMINATION OF ASH VALUES 
The ash content of crude drug is generally taken as the residue remaining 
after incineration. It usually represents the non-volatile inorganic salts like metallic 
salts and silica naturally occurring in the drug and adhering to it, but it may include 
inorganic matter added for the purpose of adulteration, contamination and 
substitution. This is important parameter for the evaluation of crude drugs. The ash 
value can be determined by three different methods like total ash, acid insoluble ash 
and water soluble ash. Sulphated ash is also ash value to find out the sulphated 
residue. 
Total ash 
Incinerated 2g of the powdered drug in a tared silica crucible at 450ºC in a 
muffle furnace until carbon completely ashes and ignited to constant weight, 
removed, cooled in a suitable dessicator for 30 minutes and weighed. Percentage of 
total ash content was calculated with reference to the air-dried drug. 
            
                          
                      
     
 
Acid insoluble ash 
Boiled the ash obtained in total ash for 5 minutes with 25 ml of dilute 
hydrochloric acid collected the insoluble matter in an ashless filter paper, washed 
with hot water and ignited at 450ºC to constant weight. Percentage of acid insoluble 
ash content was calculated with reference to the air-dried drug. 
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Water-soluble ash 
 The difference in weight between the total ash and the residue after treatment 
of the total ash with water. 
Determination of Water-soluble ash 
 To the crucible containing the total ash, add 25 ml of water and boil for 5 
minutes. Collect the insoluble matter in a sintered-glass crucible or on an ashless filter 
paper. Wash with hot water and ignite in a crucible for 15 minutes at a temperature 
not exceeding 450
0
C.  Subtract the weight of this residue in mg from the weight of 
total ash. Calculate the content of water-soluble ash in mg per g of air-dried material. 
                    
                          
                      
     
Sulphated ash 
Heated a silica crucible to redness for 10 minutes, cooled in a dessicator and 
weighed. 1g of the substance was transferred into the crucible, ignited gently at first, 
until the substance is thoroughly charred. Cooled and moistened the residue with 1ml 
of sulphuric acid, heated gently until white fumes are no longer evolved and ignited at 
800
o
C until all black particles disappeares. Allowed the crucible to cool, added a few 
drops of sulphuric acid and ignited as before to a constant weight cooled and 
weighed. 
                 
                          
                      
     
B. DETERMINATION OF EXTRACTIVE VALUES 
The method determines the amount of active constituents in a given amount of 
crude drugs when extracted with the solvents. The extraction process of crude drug 
with a particular solvent yields a solution containing different phytoconstituents. The 
composition of these phytoconstituents provides the preliminary information on the 
quality of a particular drug sample. 
Materials and methods 
 
Department of Pharmacognosy, MMC, Chennai-03 Page 42 
 
Water soluble extractive 
 Macerated 5 g of the air dried, coarsely powdered drug, with 100 ml of 
chloroform water in a closed flask for twenty-four hours, shaking frequently during 
six hours and allowed to stand for eighteen hours. Filtered and evaporated 25 ml of 
the filtrate to dryness in a tared flat bottomed shallow dish, dried at 105ºC to constant 
weight and weighed. The percentage of water-soluble extractive value with reference 
to the air-dried drug was calculated. 
                               
 
                                       
                      
     
Alcohol soluble extractive 
 Macerated 5 g of the air dried, coarsely powdered drug, with 100 ml of ethanol 
(95%) in a closed flask for twenty-four hours, shaking frequently during six hours and 
allowed to stand for eighteen hours. Filtered and evaporated 25 ml of the filtrate to 
dryness in a tared flat bottomed shallow dish, dried at 105ºC to constant weight and 
weighed. The percentage of water-soluble extractive value with reference to the air-
dried drug was calculated. 
                                 
                                       
                      
     
Ether soluble extractive 
 The type of ether soluble extractive values determined for evaluation of crud 
drugs are volatile and no-volatile ether soluble extractives .the volatile ether soluble 
represents volatile oil content of the drug, while non-volatile ether – soluble 
extractives represent resin, fixed oils or colouring matter present in drugs. The 
precentage of ether soluble extractive was calculated. 
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6.3.4. QUANTITATIVE ANALYSIS OF HEAVY METALS
45 
INSTRUMENTATION PARAMETERS: 
Instrument name: 
 Inductive coupled plasma-Optical emission spectroscopy. 
Instrument Model: 
 PE Optima 5300DV ICP-OES; Optical system Dual view-axial or radial. 
Detector system: 
 Charge coupled detector, (UV-Visible detector which is maintaining at -40º C) 
to detect the intensity of the emission line. 
Light source (Torch): 
 Positioned horizontally in the sample compartment along the central axis of 
the spectrometer optics. Changing from axial to radial viewing is a simple software 
command and is accomplished by computer control of a mirror located in the optical 
path. The torch assembly of this system comprises of two concentric quartz tubes. 
Standard alumina injector  : 2.00mm inner diameter 
Spray Chamber   : Scott type 
Nebulizer    : Cross flow gem tip 
Preparation of sample by acid digestion method: 
 50mg of powder was treated with acid mixture of sulphuric acid: water in the 
ratio of 4:1in the Kjeldahl flask and heated continuously till the solution is colourless. 
The sample mixture was then transferred in a 25ml volumetric flask and made up to 
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the volume with distilled water. Blank solution was prepared as above without 
sample. 
 The standards of Arsenic, Lead, Mercury and Cadmium were prepared as per 
the protocol and the calibration curve was developed for each of them. 
Detection: 
Samples were analyzed for the detection and quantification of the calcium, sulphate, 
borate, silver, aluminium, copper, potassium, chloride by Inductively Coupled Plasma 
Emission Spectrometry. 
6.3.5. MICROBIAL LOAD ANALYSIS
46
 
The following tests were carried out for the estimation of number of viable 
aerobic microorganisms present and for detecting the presence of designated 
microbial species in the herbal medicines. 
1. Total aerobic viable count 
 
2. Yeasts and moulds 
 
3. Escherichia coli 
4. Clostridia 
 
5. Salmonellae 
 
6. Shigella 
 
7. Pseudomonas 
 
8. Staphylococcus 
 
Pre-treatment of the raw material 
The crude raw materials were grinded to dissolve and diluted to 100ml with 
buffered sodium chloride-peptone solution adjusted the pH to 7.0. 
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Procedure 
For bacteria 
Petri dishes of 9–10 cm in diameter was used. To one dish added a mixture of 
1ml of the pre-treated raw material and about 15 ml of liquefied casein-soybean 
digest agar at a temperature not exceeding 45 °C. The material was diluted to obtain 
an expected colony count of not more than 300. The material was spreaded on the 
surface of the solidified medium, inverted them and incubated at 30–35°C for 48–72 
hours period of time. Counted the number of colonies formed and calculated the 
results using the plate with the largest number of colonies. 
For fungi 
Petri dishes of 9–10 cm in diameter was used. To one dish added a mixture of 
1ml of the pretreated material and about 15 ml of liquefied Sabouraud glucose agar 
with antibiotics at a temperature not exceeding 45°C. Spreaded the pretreated material 
on the surface of the solidified medium in a Petri dish. Diluted the material to obtain 
an expected colony count of not more than 100 and incubated them upright at 20–25 
°C for 5 days. Counted the number of colonies formed and calculated the results 
using the dish with not more than 100 colonies. 
Escherichia coli 
1ml of the material was added to 100 ml of MacConkey broth and it was 
incubated at 43–45°C for 24 hours. A subculture was prepared on a plate with 
MacConkey agar medium and incubated at 43–45°C for 24 hours. Growth of red, 
generally non-mucoid colonies of Gram negative rods, sometimes surrounded by a 
reddish zone of precipitation indicates the presence of E. coli. 
Clostridium 
10ml of the pretreated material was added to two suitable vessels, each 
containing 100ml of cooked-meat medium, heated just prior to use, to 100°C for a 
few minutes and cooled to 37°C. To distinguish between sporing and non-sporing 
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organisms, one vessel was sealed with a layer of sterile paraffin immediately. The 
other vessel was heated at 65°C for 30 minutes and then similarly sealed. Both 
vessels were incubated at 35–37°C and examined every 24 hours for up to 4 days. 
Growth of sporing organisms occurs in the vessel which was heated after inoculation. 
If no growth occurs in either of the vessels, the sample passes the test for absence of 
Clostridia and other anaerobic bacteria. 
Salmonella 
The pre-treated plant material or product was incubated at 35–37°C for 5–24 
hours, as appropriate for enrichment. 
Primary test 
10 ml of the enriched culture was transferred to 100 ml of tetrathionate bile 
brilliant green broth and was incubated at 42–43°C for 24 hours. Subcultures were 
prepared on two agar media: deoxycholate citrate agar and brilliant green agar. Then, 
they were incubated at 35–37°C for 24 hours. The well-developed, colourless 
colonies in deoxycholate citrate agar medium and the small, transparent and 
colourless, or opaque, pink or white (frequently surrounded by a pink to red zone) 
colonies in Brilliant green agar medium indicates the presence of Salmonella spp. 
Shigella 
Direct inoculation of agar plates 
3 loopful of the pretreated material was transferred to the plates and were 
incubated at 35–37°C for 24 hours. A general purpose plating medium of low 
selectivity and one of high selectivity was inoculated. Mac Conkey agar was used as a 
medium of low selectivity. Mac Conkey agar with 1µg/ml of potassium tellurite was 
used for S.dysenteriae type 1 (Sd1). A 
small inoculum was used. It was incubated at 35–37°C for 24 hours. Xylose-lysine-
desoxycholate (XLD) agar was used as a medium of high selectivity for isolation of 
Shigella. 
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Identification of colonies on plating media 
Colonies suspicious for Shigella will appear as follows: 
 Mac Conkey agar: convex, colourless, 2–3 mm 
 
 XLD agar: red, smooth, 1–2 mm 
 
If the colonies found well seperated of typical appearance from each of the plating 
media it can be taken for further testing by making a mark on the bottom of the 
petridish. 
Inoculation of Triple sugar iron agar (TSI) 
Three characteristic colonies from the plating media was picked and 
inoculated into Triple sugar iron agar (TSI) as follows: stabbed the butt and then 
streaked the slant with a zigzag configuration. The tubes were properly labelled. It 
was then incubated overnight. On the following morning, the reactions in the TSI 
tubes was examined. 
Tubes suspicious for Shigella will have an acid (yellow) but and an alkaline 
(red) slant. They will not produce gas (no bubbles or cracks in the agar) and will not 
produce hydrogen sulfide (no black along the stab line). 
Pseudomonas aeruginosa 
1ml of the pretreated material was inoculated in 100ml of soybean-casein 
digest medium. Mixed and incubated at 35–37°C for 24–48 hours. Prepared a 
subculture on a plate of cetrimide agar and incubated at 35–37°C for 24–48 hours. 
If no growth of microorganisms is detected, the material passes the test. If 
growth of colonies of Gram-negative rods occurs, usually with a greenish 
fluorescence. 
Staphylococcus aureus 
Pretreated material was incubated at 35–37 °C for 24–48 hours. 
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The material passes the test if no growth of microorganisms is detected. Black 
colonies of Gram-positive cocci often surrounded by clear zones may indicate the 
presence of Staphylococcus aureus. 
6.4. PHYTOCHEMICAL STUDIES
47,48 
Herb is a biosynthetic laboratory, which contains chemical compounds such 
as carbohydrates, proteins and lipids that are utilized as food. It also contains 
secondary products like glycosides, alkaloids, flavonoids, tannins etc. The detection 
of these active principles in medicinal plants plays a strategic role in the 
phytochemical investigation of crude drugs and extracts and is very important in 
regard to their potential pharmacological effects. These tests facilitate the quantitative 
estimation and qualitative separation of pharmacologically active chemical 
compounds and subsequently may lead to the drug discovery and development. 
All the plant raw materials were subjected to preliminary phytochemical 
screening for the detection of various plant constituents. 
6.4.1 PRELIMINARY PHYTOCHEMICAL SCREENING  
A. Triterpenoids 
Salkowski test - Powdered crude drug was treated with few drops of 
concentrated sulphuric acid, formation of yellow colour indicates the presence of 
triterpenoids.  
B. Flavones 
Shinoda test - To the powdered crude drug, few magnesium turnings and few 
drops of concentrated hydrochloric acid were added and boiled for five minutes 
formation of red coloration indicates the presence of flavones. 
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C. Alkaloids 
Dragendorff’s reagent - To the powdered crude drug, few drops of 
potassium bismuth iodide solution was added, reddish brown colour indicates the 
presence of alkaloids. 
D. Carbohydrates 
Molisch’s test - In a test tube containing powdered drug, 2 ml of distilled 
water and 2 drops of freshly prepared 20% alcoholic solution of α- napthol were 
added. Mixed well and added 2ml of concentrated sulphuric acid along the sides of 
the test tube. Formation of red violet ring, which disappears on addition of excess 
alkali solution, indicates the presence of carbohydrates. 
E. Glycosides 
Extracted 200 mg of drug with 5 ml dilute sulphuric acid by warming on a 
water bath, filtered and neutralized the acid extract with 5% solution of sodium 
hydroxide. 1ml of Fehling’s solution A and B were added until it became alkaline 
(test with pH paper) and heated on a water bath for 2 minutes. Formation of red 
precipitate was observed, which indicates the presence of glycosides. 
F. Phenols 
Ferric chloride test - Dissolved a small quantity of the drug with 2ml of 
distilled water, added a few drops 10% aqueous ferric chloride solution. A blue or 
green colour was produced, which indicates the presence of phenols. 
G. Proteins (Biuret test) 
 To 1ml of ethanolic extract of the drug, 5 to 8 drops of copper sulphate 
solution (10%) was added. Formation of violet colour indicates the presence of 
proteins. 
H. Resin 
Dissolved a small quantity of the ethanolic extract of the drug with 5 -10 ml of 
acetic anhydride by gently heating the solution. Cooled and added 0.05 ml of 
concentrated sulphuric acid. A bright purplish red colour was seen, which rapidly 
changed to violet indicates the presence of resins. 
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I. Saponins 
To 5 ml of an extract of the drug, a drop of sodium bicarbonate solution was 
added. Shake the mixture vigorously and left it for 3 minutes. Honey comb like froth 
developed indicates the presence of saponins. 
J. Tannins 
The powdered drug was mixed with basic lead acetate solution. Formation of 
white precipitate, which indicates the presence of Tannins. 
K. Steroids 
Libermann Burchard’s test - The powdered drug was treated with few drops 
of acetic anhydride, boiled and cooled and added concentrated sulphuric acid from the 
side of the test tube. A brown ring was formed at the junction two layers and upper 
layer turns green indicates the presence of steroids. 
6.4.2. PREPARATION OF EXTRACT
 
Extraction is the preliminary step involved in the phytochemical studies. 
Ethanol proves to the universal solvent. As the present study utilizes a combination of 
herbs, ethanol was opted for the extraction of the active constituents from the 
individual plants separately. The method of extraction is Hot Percolation method. 
HOT PERCOLATION METHOD 
About 200g of coarsely powdered parts of the plant was extracted with 
Ethanol at 60-70°C. Extract of individual plants were concentrated using rotary 
vacuum evaporator. The percentage yield, colour and consistency of all the extracts 
were noted and were taken up for further detailed  phytochemical and 
pharmacological screening. 
6.4.3. FLUORESCENCE ANALYSIS 
47,48
 
In near ultra violet region some of the phytoconstituents shows more or less 
brilliant colouration when exposed to radiation. The amount of ultra violet light 
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normally present with visible light is sufficient to produce fluorescence. The 
phenomenon of emitting visible wavelengths as a result of being excited by radiation 
of a different wavelength known as fluorescence. This phenomenon make use for the 
qualitative examination of herbal crude drugs by using ultra violet light. 
The presence of constituents with such properties often gives the drug, a 
characteristic appearance when exposed to ultra violet light, radiation which is 
reflected as brilliant fluorescence. This fluorescence technique useful for the detection 
of adulteration in crude drugs. 
Raw materials used for the polyherbal capsule preparation were tested for any 
colour changes under UV light. Samples were tested as such and after treating with 
organic solvents, alkali and acidic solutions and viewed under ordinary light, short 
UV (254 nm) and long UV (365 nm) and studied for its fluorescence property. 
CHROMATOGRAPHY
49-51
 
 
Chromatographic fingerprinting has been in use for a long time for single 
chemical entity drug substances. Recently it has become one of the most powerful 
tools for quality control of herbal medicines. The use of chromatographic 
fingerprinting for herbal drugs tends to focus on identification and assessment of the 
stability of the chemical constituents observed by various chromatography techniques 
such as HPLC, TLC, HPTLC, GC, capillary electrophoresis.
 
6.4.4. THIN LAYER CHROMATOGRAPHY
 
Principle 
 It consists of a thin layer of adsorbent coated on a chromatographic plate, the 
mobile phase (developing solvent) flows against gravitational force by means of 
capillary action. The separation is mainly on the differential migration that occurs 
when the solvent flows along the thin layer of stationary phase. The principle 
involved thin layer chromatography is adsorption. 
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Thin layer chromatographic study 
 The ethanolic extracts of Berberis aristata, Terminalia chebula, Emblica 
officinalis, Terminalia belerica and  Cyperus rotundus were subjected to thin layer 
chromatography (TLC) as per conventional method using silica gel 60F254, 5x3 cm 
(Merck). Plate markings were made with soft pencil. Glass capillary tubes were used 
to spot the extract in TLC plates. Different solvent systems ranging from lower to 
higher polarities were tested for the separation of bioactive components. 
  In the TLC chamber the solvent system viz Butanol: Acetic acid: Aqueous 
(40:10: 20) were used.  After pre-saturation with mobile phase for 30 min the plates 
were kept inside the chamber and the elution was performed using above mentioned 
solvent systems. After completion of the elution the plates were dried and subjected to 
visualized under UV chamber and sprayed using different spray reagents.  
Rf values determined by using following formula: 
Rf  = Distance travelled by the solute / Distance travelled by the solvent. 
6.4.5. HPTLC FINGERPRINT PROFILE
 
 
HPTLC is one of the advanced and versatile chromatographic technique which 
helps in the identification of compound and thereby authentication of purity of herbal 
drugs. It is very quick process. In addition to qualitative detection, HPTLC also 
provides semi-quantitative information on major active constituents of a drug thus 
enabling an assessment of drug quality. 
HPTLC serves as a convenient tool for finding the distribution pattern of the 
phytoconstituents which is unique to each plant. The finger print obtained is suitable 
for monitoring the identity and purity of drugs and for detecting adulteration and 
substitution. HPTLC technique is helpful in order to check the identity, purity and 
standardize the quantity of active principles present in the herbal extracts. 
Sample Preparation: 1mg of Polyherbal extract was dissolved in 1 ml of methanol.  
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Developing Solvent System: A number of solvent systems were tried, for extract. 
The satisfactory resolution obtained for the phytochemical constituent alkaloid was in 
the solvent butanol-acetic acid-water (4:1:5). 
Chromatography: Chromatography was performed on silica gel 60 F254 TLC pre-
coated plates using Hamilton syringe and CAMAG LINOMAT 5 instrument. 2 µl of 
standard solution and 2 µl of the test solution (extract) were loaded as 5 mm band 
length in the 4×10 glass plates, with the help of a CAMAG LIWOMAT 5 sample 
applicator at the distance of 10 mm from the edge of the plates.  
Development of Chromatogram: After the application of sample, the chromatogram 
was developed in Twin trough glass chamber 10x10 cm saturated with previously 
equilibrated mobile phase for 30 minutes. The chromatographic conditions were 
previously optimized to active the best resolution and peak shape. 
Detection of Spots: The air-dried plates were viewed in ultraviolet radiation to mid-
day light. The chromatograms were scanned by densitometer at 420 nm. Quercetin 
was used as the reference standard. The plates were kept in Photo-documentation 
chamber (CAMAG REPROSTAR 3) and captured the images at White light, UV 254 
nm. After scanning the plates the Peak table, Peak display and Peak densitogram were 
recorded. The retention factor (Rf) was calculated by the WinCats software.  
6.5. DEVELOPMENT OF FORMULATION 
The ethanolic extracts of Berberis aristata, Terminalia chebula, Emblica 
officinalis, Terminalia belerica and  Cyperus rotundus were subjected to freeze 
drying process .The extracts were dried for a period of time according to their rate of 
drying . The lyophiliser was made utilized in the Pharmaceutics Laboratory, of our 
college. Diluents like, Microcrystalline cellulose, Magnesium stearate, Lactose,starch 
were dried.  
All active ingredients were weighed according to the formula, mixed with 
adsorbent magnesium carbonate followed by diluents and preservatives like Sodium 
methyl paraben and bronopol as specified in formula were mixed well. The mixture 
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was blended thoroughly for 30 minutes. Then the powder was transferred to the 
polythene bags and labelled for further studies. 
Table 2. PROPOSED STRENGTH OF FORMULATION 
S.NO. ACTIVE INGREDIENTS 
STRENGTH 
(in mg) 
1 Berberis aristata  50 
2 Terminalia chebula 100 
3 Emblica officinalis 120 
4 Terminalia belerica 120 
5 Cyperus rotundus 80 
 
6.5. 1. PREFORMULATION STUDIES
52 
 Prior to formulation, it is essential that fundamental physical and chemical 
properties of the drug molecule and other derived properties of the drug powder are 
determined. This information decides many of the subsequent events and approaches 
in formulation development. This first learning is known as Preformulation. It aims to 
optimize the process of turning a drug into a drug product. During preformulation the 
physiochemical properties of the drug candidate are determined. 
Definition 
Preformulation involves the application of biopharmaceutical principles to the 
physicochemical parameters of drug substance are characterized with the goal of 
designing optimum drug delivery system. 
Before beginning the formal preformulation programs the manufacturing 
scientist must ensure the following factors: 
 The amount of drug available 
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 The physicochemical properties of the drug already known. 
 
 Therapeutic category and anticipated dose of compound. 
 
 The nature of information, a formulation should have or would like to 
have. 
 
 SELECTION OF THE EXCIPIENTS
53 
The majority of materials filled in the capsules are formulated as powders that 
are typically mixtures of the active ingredients together with a combination of 
different types of excipients. This is so because placing powders into hard gelatin 
capsules often lead to improved bioavailability owing to a higher porosity of the filled 
mass and the requirements for powder flow is less stringent for filling capsules than 
for tabletting. Normally, there are three types of excipients used in powder filled 
capsules i.e. diluents, glidants and lubricants. 
Diluents: 
 Diluents/Fillers are added where the quantity of active ingredient is less (or) 
difficult to filling. Common tablet/capsule filler include Lactose, Dicalcium 
phosphate, Microcrystalline cellulose, etc. 
Lubricants: 
 They reduce friction during the filling process. In addition, they aid in 
preventing adherence of capsule material. Magnesium Stearate, Stearic acid, 
Hydrogenised vegetable oils and talc are commonly used lubricants. 
Glidant: 
It is used to improve flow of the powder materials by reducing the friction between 
the particles. The most effective glidants are the Colloidal silicon dioxide, Talc and 
Starch. 
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Preservatives: 
 The preservatives are added to herbal formulation to prevent contamination, 
deterioration and spoilage by bacteria, fungal and other microorganisms. The most 
effective preservatives are the sodium methyl paraben, sodium propyl paraben, 
sodium benzoate and bronopol. 
 FLOW PROPERTY MEASUREMENTS
54,55 
 The flow property of the blended powder is an important parameter to be 
measured since it affects the uniformity of dose. It was assessed by the following 
parameters. 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner's ratio 
 Angle of repose 
 
Bulk density (ρb) 
 It is determined by measuring the volume of a known mass of powder sample 
that has been passed through a screen into a graduated cylinder or through a volume 
measuring apparatus into a cup. It is expressed in g/ml and is given by, 
ρb = M/Vo 
Where, M - is the mass of powder 
Vo- is the bulk volume of the powder. 
The inter particle interactions that influence the bulking properties of a powder are 
also the interactions that interfere with powder flow, a comparison of the bulk and 
tapped densities can give a measure of the relative importance of these interactions in 
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a given powder. Such a comparison is often used as an index of the ability of the 
powder to flow. 
Tapped density (ρt) 
 It is achieved by mechanically tapping a measuring cylinder containing a 
powder sample. After observing the initial volume, the cylinder is mechanically 
tapped and volume readings are taken until little further volume change is 
observed.The mechanical tapping is achieved by raising the cylinder and allowing it 
to drop under its own weight at a specific distance.The tapped volume was measured 
by tapping the powder to constant volume. It is expressed in g/ml and is given 
ρt = M/Vt 
Where, M - Mass of powder and Vt- Tapped volume of the powder 
Compressibility index: (CI) 
 Compressibility is the ability of powder to decrease in volume under pressure. 
Compressibility is a measure that obtained from density determination. Weighed 
quantity of granules was transferred to 50 ml graduated cylinder, volume occupied by 
granules was noted down. Then cylinder was subjected to 500/ 750 and 1250 taps. 
The difference between two tabs should be less than 2%. The percentage 
Compressibility Index is calculated by using formula. 
CI = Vo-Vi ×100/Vo 
Where, Vo- Untapped density; Vi- Tapped density 
Hausner’s Ratio 
 It is measurement of frictional resistance of the granular material. The Ideal 
range should be 1.2 -1.5, it was determined by the ratio of tapped density and bulk 
density.                   Hausner’s Ratio = Vi / Vo 
Where, Vo -Untapped density, Vi -Tapped density 
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Angle of repose 
 The tangent of angle of repose is equal to the coefficient of friction between 
the particles. Hence the rougher and more irregular the surface of particles, the greater 
will be angle of repose. For determination of angle of repose (θ), the blends were 
poured through the walls of a funnel which was fixed at a position such that its lower 
tip was at a height of exactly 2.0 cm above a hard surface. The drug or the blends 
were poured till the time when upper tip of the pile surface touched the lower tip of 
the funnel. Angle of repose was calculated using following equation. 
Tan θ = h/r, 
θ = tan-1 (h/r) 
Where, θ - angle of repose, h- height in cm and r- radius in cm. 
 Based on the Angle of repose, Compressibility index and Hausner’s ratio, the flow 
property of the granules can be characterized. 
Table 3:Angle of Repose, Compressibility Index and Hausner’s Ratio 
Flow property 
Angle 
repose 
Compressibility 
Index 
Hausner’s ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.46-1.59 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >66 >38 >1.60 
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DEVELOPMENT OF FORMULATION -TRIAL BATCHES 
Four trial batches of  capsules were formulated by varying the composition of 
the excipients proportions for excellent flow property. 
Table 4. DEVELOPMENT OF FORMULATION 
S.NO 
 
 
MATERIALS 
TRIAL-1 
(mg) 
TRIAL-2 
(mg) 
TRIAL-3 
(mg) 
 
TRIAL-
4 (mg) 
1 Berberis aristata  50 50 50 50 
2 Terminalia chebula 100 100 100 100 
3 Emblica officinalis 120 120 120 120 
4 Terminalia belerica 120 120 120 120 
5 Cyperus rotundus 80 80 80 80 
6 Lactose 35 40 55 35 
7 
Micro crystalline 
cellulose 
18 20 25 10 
8 
Magnesium 
carbonate 
1.2 3 4.5 5 
9 Starch paste Aq Aq Aq Aq 
10 
Sodium methyl 
paraben 
0.5 0.5 0.5 0.5 
11 Bronopol 0.5 0.5 0.5 0.5 
 
The blended powder of all four trial batches were analysed for its flow 
characteristics like bulk density, tapped density, compressibility index, Hausner’s 
ratio and  Angle of repose.  
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From the above trial batches, the trial batch 4th trial was found to be the 
perfect batch and it was selected for the consideration of further studies. 
Table :5 Final Batch 
S.NO 
 
 
MATERIALS TRAIL 
IV(mg) 
1 Berberis aristata  50 
2 Terminalia chebula 100 
3 Emblica officinalis 120 
4 Terminalia belerica 120 
5 Cyperus rotundus 80 
6 Lactose 35 
7 Micro crystalline cellulose 10 
8 Magnesium Carbonate 5 
9 Starch paste Aq 
10 Sodium methyl paraben 0.5 
11 Bronopol 0.5 
 
6.5.2. FORMULATION OF CAPSULES
54-57
 
Capsule is the most versatile of all dosage forms. Capsules are solid dosage 
form in which one or more medicinal and inert ingredients are enclosed in a small 
shell usually made of gelatin. There are two types of capsules, “hard” and “soft”. The 
hard capsule is also called “two piece” as it consists of two pieces in the form of small 
cylinders closed at one end, the shorter piece is called the “cap” which fits over the 
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open end of the longer piece, called the “body”. The soft gelatin capsule is also called 
as “one piece”. Capsules are available in many sizes to provide dosing flexibility.  
SELECTION OF CAPSULE SIZE 
54,55 
The volume of material to be filled into the capsule should be determined. 
Generally, capsules of sizes “0” to “4” were readily available in the market and the 
relationship between the capsule size and related body volume to be known at the 
development stage. For pharmaceutical products it is unusual to use a size larger than 
“0” because of the difficulty in swallowing larger size capsules, whilst size “5” is 
rarely used due to difficulties in the automatic filling process. Capsule of size “0” 
were selected to fill the polyherbal formulation. 
CAPSULE FILLING 
 The formulated granules were filled in"0" size capsules to an average net 
content weight 520mg per capsule by manual filling method. 
 The capsules were then dedusted, transferred into polythene bags, labelled and 
the samples were evaluated as per testing requirements. 
6.6.  STANDARDISATION OF POLYHERBAL CAPSULES 
58 
The developed polyherbal capsules were standardised for its 
Description, uniformity of weight, disintegration time, moisture content, pH, 
physicochemical parameters, phytochemical studies, fluorescence analysis, heavy 
metal analysis and microbial load analysis. Determination of uniformity of weight, 
disintegration time and moisture content of capsules were carried out as per Indian 
pharmacopoeial procedures. 
 
6.6.1. DESCRIPTION 
The general appearance of a capsule, its visual identity and overall 
“elegance” is essential for consumer acceptance. The color, shape, odor, surface 
texture and legibility of any identifying marking are all noted for the capsules 
prepared. 
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6.6.2. pH 
The pH value of a solution was determined potentiometrically by means of a 
digital pH meter. The pH meter was calibrated using buffers of 4, 9 and 7 pH. 1g of 
capsule content was taken and dissolved in 100ml demineralized water. The 
electrodes were immersed in the solution and the pH is measured. 
 6.6.3. AVERAGE WEIGHT & UNIFORMITY OF WEIGHT 
20 individual units were selected at random and this content was 
weighed and their average weight was calculated. Not more than two of the 
individual weights deviate from the average weight by more than the percentage 
shown in the table and none deviates by more than twice that percentage. 
 
Table 6. SPECIFICATION OF AVERAGE & UNIFORMITY OF WEIGHT 
S.NO DOSAGE FORM AVERAGE % DEVIATION 
  WEIGHT  
1. Capsules <300mg 10% 
  >300 mg 7.5% 
    
 
6.6.4. DISINTEGRATION TIME 
This test is done to measure the time taken by the drug to disintegrate in the 
body. This is done to determine whether the capsule disintegrates within the 
prescribed time when placed in a liquid medium under the prescribed experimental 
conditions. One each capsule was added to each of the six tubes of the basket and a 
disc was added to each of the tube. The tubes were dipped in 0.1N HCl solution 
maintained at 37°C. 
 
Materials and methods 
 
Department of Pharmacognosy, MMC, Chennai-03 Page 63 
 
6.6.5. PHYSICOCHEMICAL PARAMETERS 
43
 
Physicochemical parameters like loss on drying, ash and extractive values 
were carried out as per pharmacopoeial procedures as discussed in earlier.(6.4.3) 
6.6.6. PHYTOCHEMICAL STUDIES 
 
I. QUALITATIVE PHYTOCHEMICAL ANALYSIS were carried out to detect 
the presence of phytoconstituents in the polyherbal formulation. They were discussed 
in earlier chapter
47,48
(6.4.4) 
6.6.7. II. QUANTITATIVE ESTIMATION OF TOTAL PHENOLIC,  
FLAVONOID AND TANNINS CONTENT
59,60,61 
ESTIMATION OF FLAVONOIDS
  
 The total flavonoid content is usually determined spectrophotometrically using 
Ultra-violet spectroscopy. 
Preparation of Standard Stock solution 
 Accurately weighed 25 mg of Quercetin standard transferred to 100 ml of 
volumetric flask and dissolved with dimethyl sulfoxide(DMSO). The serial dilution 
(12.5μg/ml to 200μg/ml ) were made with dimethyl sulfoxide. 
Preparation Of Test Solution 
 The Polyherbal formulation  was weighed accurately equal to the weight of 
Standard Quercetin and transferred to 100 ml volumetric flask and the extract 
dissolved with dimethyl sulfoxide (DMSO). The serial dilution (12.5μg/ml to 
2005μg/ml) were made with dimethyl sulfoxide. 
PROCEDURE 
 From the prepared solution of standard and test solutions 2ml was withdrawn 
from each concentration to the test tube and added equal volume of 2% Aluminium 
Chloride solution to every single concentration. Incubate the solution about 10 minute 
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at ambient temperature. After 10 minute, measure the absorbance 
spectrophotometrically at 435 nm with the standard and test sample solutions. 
ESTIMATION OF PHENOLIC CONSTITUENTS 
 Total phenolic content of the extracts were determined using Folin –
Ciocalteu’s assay. 0.5ml extract solutions were mixed with 2.5ml of 10 fold diluted 
Folin Ciocalteu’s reagent and 2.5ml of 7.5% sodium carbonate. After incubation at 
40°c for 30 minutes, the absorbance of the reaction mixtures was measured at 765nm 
in a spectrophotometer. Three replicates were made for each test sample. Gallic acid 
was used as a standard and total phenolic content of the extract was expressed in mg 
of Gallic acid equivalents (mg GAE/g extract) 
ESTIMATION OF TANNIN CONTENT 
 The tannin content was determined by using FeCl3 and gelatin tests 0.1g of the 
extracts were transferred to a 100ml flask, 50ml of water was added and boiled for 
30min. After filtration with cotton filter, filtrate was transferred to a 500ml flask and 
the volume was made up to the mark with distilled water. 0.5 ml aliquots were 
transferred to vials, 1ml of 1% K3Fe (CN)6and 1 ml of 1% FeCl3 were added and the 
volume was made up to 10ml with distilled water. After 5 min absorbance was 
measured at 510nm against a reagent blank spectrophotometer and concentration of 
tannins in the test sample was determined and expressed as mg equivalent of tannic 
acid per gram of sample. 
Quantitative analysis of  Heavy metal 
The formulation was analyzed for its heavy metals as discussed earlier 
(6.3.4) 
MICROBIAL LOAD ANALYSIS 
For the safe use of poly herbal capsules microbial count were done and 
checked whether total Total aerobic viable count,Yeasts and moulds were within the 
prescribed limits and the microorganisms Escherichia coli, Clostridia, Salmonellae, 
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Shigella, Pseudomonas, Staphylococcus were absent in the finished formulation. The 
procedure was discussed earlier (6.3.5)  
6.7. PHARMACOLOGICAL EVALUATION 
 The protocol for conducting the in vivo study in female adult albino wistar rats 
was approved by the Institutional Ethical Committee (IEC) of the Madras Medical 
College, Chennai-600003, CPSEA registration number 
1917/ReBi/16/cpcea/25.10.2016 vide Roc. No.13/AEL/IAEC/MMC,Date:12.09.2017. 
6.7.1.IN VITRO ANTI – DIABETIC ACTIVITY62 
α-amylase inhibition assay 
α-amylase was dissolved in phosphate buffer saline (PBS, 0.02 mol/L, pH 6.8) 
at a concentration of 0.1 mg/mL. Various concentrations of sample solutions (0.25 
mL) were mixed with α-amylase solution (0.010 mL) and incubated at 37 °C for 5 
min. Then the reaction was initiated by adding 0.1 mL 1.0% (w/v) starch substrate 
solution to the incubation medium. After incubation at 37 °C for 3 min, the reaction 
was stopped by adding 1 mL DNS reagent (1% Dinitrosalicylic acid,  0.05% Na2SO3 
and 1% NaOH solution) to the reaction mixture and boiling at 100 °C for 5 min. After 
cooling to room temperature, the absorbance (Abs) at 540 nm was recorded by a 
spectrophotometer. The inhibition percentage was calculated by the following 
equation: 
 Inhibition (%) = [(Abs1 − Abs2)/Abs1] × 100 
   where, Abs1=sample and Abs2 = control.  
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6.7.2. IN VIVO ANTIDIABETIC ACTIVITY 
 ACUTE TOXICITY STUDY
63,64
 
The acute toxicity study was designed as per the OECD Guideline for Testing 
of Chemicals, Acute Oral Toxicity (Acute Toxic Class Method), Guideline 423. 
Principle and purposes 
Acute toxicity testing determines the toxicity of a chemical or drug substances 
after single administration. The test is based on stepwise procedure with use of 
minimum number of animals per step; sufficient information is obtained on the acute 
toxicity of the test substance to enable its classification. The substance was 
administered orally to a group of experimental animals at one of the defined dose. 
The substance was tested using a stepwise procedure, each step using three animals of 
a single sex. Absence or presence of compound-related mortality of the animals dosed 
at one step was used to determine the next step, i.e. 
 No further testing is needed 
 
 Dosing of three additional animals, with the same dose 
 
 Dosing of three additional animals at the next higher or the 
next lower dose levels 
Experimental animals 
 Healthy adult non pregnant female wistar albino rats weighing between 150-
200g were selected for the study. For all the three animals water was provided ad 
libitum and food was withheld overnight prior to dosing. 
Selection of dose levels and administration of doses 
 Being a traditional herbal medicine, the mortality was unlikely at the highest 
starting dose level (2000mg/kg body weight). Hence a limit test at one dose level of 
2000mg/kg body weight was conducted in all the three animals. 
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TEST PROCEDURE WITH A STARTING DOSE OF 2000 mg/kg  
BODY WEIGHT(OECD/OCDE 423) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test procedure with a starting dose of 2000 mg/kg body weight 
(OECD/OCDE 423) 
Observation 
The animals were observed individually after dosing once during the first 30 
minutes, periodically for the first 24 hours, with special attention given during the 
first 4 hours, and daily there-after, for a total of 14 days. The following clinical 
observations were made and recorded. 
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Toxic signs 
All the rats were observed for any toxic signs. 
Pre-terminal deaths 
All the rats were observed for any pre-terminal deaths 
Body weight 
Individual body weight was recorded for all the animals once in a week 
Cage side observation 
The faeces color, faeces consistency, changes in skin, fur and eyes of the 
animals were observed once in a week. 
Physical examination 
Physical observation were observed once in a week. 
ANTIDIABETIC EFFECT OF HERBAL FORMULATION IN  
STREPTOZOTOCIN  AND  NICOTIMANIDE  INDUCED  DIABETIC  
RATS
65-71 
The Albino Wistar rats were divided into four different Groups of six animals each as 
follows.  
Group I : Diabetic rats treated with Distilled water 
Group II : Diabetic  rats  treated  with  PHF (200 mg/kg) 
Group III : Diabetic rats treated with PHF (400 mg/kg) 
Group IV : Diabetic  rats treated with Glibenclamide  (0.25 mg/kg).  
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Table: 7  Animal Experimental Design 
S. No Group 
Name of the 
drug 
Dose No of 
animals 
Duration of 
dosage (days) 
1 Group –1 Distilled Water 2ml p.o 6 28 
2 Group –2 Polyherbal 
formulation 
200mg/kg 
p.o 
6 28 
3 Group – 3 
Polyherbal 
formulation 
400mg/kg 
p.o 
6 28 
4 Group – 4 
Standard 
(glibenclamide) 
0.25mg/kg 
p.o 
6 28 
  
 Diabetes  was  induced  in overnight fasted rats  by administering single 
intraperitoneal (i.p.) injection of freshly prepared Streptozotocin (STZ) 50 mg/kg 
body weight, followed by 120 mg/kg of Nicotimanide (NIC) in 0.1 M citrate buffer 
(pH 4.5) in a volume of 0.5 ml/kg body weight. Diabetes was confirmed in the STZ + 
NIC treated rats by measuring fasting blood glucose levels after 48 hrs of induction. 
After 24 hrs of STZ + NIC injection, the rats were given 5% w/v of  glucose solution 
(2 ml/kg body weight) to prevent hypoglycemic mortality.  
 Rats with fasting blood glucose of more than 200 mg/dl were considered as 
diabetics and they were divided randomly  into four different groups. The standard 
(glibenclamide) and  herbal formulation were suspended  in distilled water and 
administered once daily through oral gavage  for 28 consecutive days.  Weekly body 
weight variations were monitored for all the experimental animals. 
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BIOCHEMICAL ESTIMATION
 
 The blood samples were collected on initial, 7th, 14th and 21st and 28
th days of 
the treatment, through the tail vein of rats by pricking and were immediately used for 
the estimation of blood glucose with a glucometer. 
 At the end of the experiment, the  blood  sample was withdrawn from all the 
experimental animals through retro orbital plexus  puncture  for  biochemical analysis. 
Statistical Analysis 
All the data expressed as mean ± SEM were analysed by Oneway Analysis of 
Variance(ANOVA) followed by Dunnett’s t test  for  multiple comparison. The 
statistical analyses were performed using Graphpad Prism version 7.04 of computer 
software.  P values <0.05 were considered as statistically significant. 
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7. RESULTS AND DISCUSSION 
  
7.1. RAW MATERIAL STANDARDIZATION 
7.1. 1. ORGANOLEPTIC EVALUATION 
 
Table : 8 ORGANOLEPTIC CHARACTERS 
 
S.NO 
NAME OF 
THE 
PLANT 
NATURE COLOUR ODOUR TASTE 
1 
Berberis 
aristata 
Coarse 
powder 
Pale 
Yellowish 
brown 
Odourless Bitter 
2 
Terminalia 
chebula 
Coarse 
powder 
Dull Yellow Odourless 
Astringent, 
slightly 
bitter 
3 
Emblica 
officinalis 
Coarse 
powder 
Grey to black Odourless Sore and 
Astingent 
4 
Terminalia 
belerica 
Coarse 
powder 
Dark brown 
to black 
None Astringent 
5 
Cyperus 
rotundus 
Coarse 
powder 
Dark black Pleasant Pleasant 
 
7.1.2. MICROSCOPICAL EVALUATION 
Table 9. POWDER MICROSCOPY 
 
S.NO PLANT NAME 
OBSERVATION 
1 Berberis aristata     
(dried stem) 
Presence of Non-lignified elements: Fibres, stone 
cells, Thick walled fibres, Parenchyma with 
crystals. Lignified elements: Cork cells in oblique 
view,  Pitted vessel fragment, Fibre fragment, 
Vessel, Tracheid, Sclereid. 
2. Terminalia 
chebula (pericarp 
of fruit) 
Presence of Non-lignified elements: Epicarp, 
Thick walled parenchyma, Lignified elements: 
Different types of sclereids, Fibro-sclereids, Pitted 
tracheids. 
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3. Emblica officinalis 
(pericarp of fruit) 
Presence of Non-lignified elements: Epicarp, 
Thick walled parenchyma, Fibre, 
Parenchyma.Lignified elements: Sclereids of 
different types 
4. Terminalia 
belerica (pericarp 
of fruit) 
Presence of Non-lignified elements: Trichome, 
Epicarp, Parenchyma with tannin, Tracheids, 
Vessels. Lignified elements: Vessels, Sclereids, 
Fibro-sclereid 
5. Cyperus rotundus     
(dried rhizome) 
Presence of Non-lignified elements: Cork, 
Aerenchyma from root, Tracheidal fibres, Vessels. 
Lignified elements: Group of sclereids, 
Parenchyma. 
 
Figure:18.  Characters from Berberis aristata DC. - Dried stem 
18.1 Non-lignified elements 
  
18.1.1 Fibres 18.1.2 Stone cells 
 
  
18.1.3 Thick walled fibres 18.1.4 Parenchyma with crystals 
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18.2 Lignified elements 
 
  
8.2.1 Cork cells in oblique view 8.2.2 Pitted vessel fragment 
 
  
8.2.3 Fibre fragment 8.2.4 Vessel 
 
  
8.2.5 Tracheid 8.2.6 Sclereid 
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Figure: 19 Characters from Terminalia chebula (Gaertn.) Retz. - fruit 
19.1 Non-lignified elements 
 
  
19.1.1 Epicarp 19.1.2 Thick walled parenchyma 
 
19.2 Lignified elements 
 
 
 
19.2.1 Different types of sclereids 
 
  
19.2.2 Fibro-sclereids 19.2.3 Pitted tracheids 
 
 
 
 
 
 
Cortical parenchyma 
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Figure.20 Characters from Emblica officinalis Gaertn. – pericarp 
 
20.1 Non-lignified elements 
 
  
 
20.1.1 Epicarp 
 
  
20.1.3 Thick walled parenchyma 20.1.4 Fibre 
  
20.1.5 Parenchyma 
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20.2 Lignified elements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20.2.1 Sclereids of different types 
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Figure:21 Characters from Terminalia bellerica (Gaertn.) Roxb. - fruit 
 
21.1 Non-lignified elements 
 
  
21.1.1 Trichome 21.1.2 Epicarp 
  
 
21.1.3 Parenchyma with tannin 
 
 
21.1.4 Tracheids 
  
 
21.1.5 Vessels 
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21.2 Lignified elements 
  
21.2.1 Vessels 
  
21.2.2 Sclereids 
 
21.2.3 Fibro-sclereid 
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Figure: 22 Characters from Cyperus rotundus L. - rhizome 
22.1 Non-lignified elements 
  
22.1.1 Cork 22.1.2 Aerenchyma from root 
  
22.1.3 Tracheidal fibres 
 
22.1.4 Vessels 
22.2 Lignified elements 
  
22.2.1 Group of sclereids 22.2.2 Parenchyma 
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7.1.3. PHYSIO -CHEMICAL EVALUATION 
 
 LOSS ON DRYING 
 
Loss on drying for the raw materials were done. The results obtained and the 
standared values are given in table. 
Table :10  Loss on drying   
S.NO PLANT NAME LOD (% w/w) 
ACCEPTABLE 
LIMITS(w/w %) 
1 Berberis aristata 
2.74±0.59 
NMT 8 
2 Terminalia chebula 3.67±0.12 NMT 8 
3 Emblica officinalis 
4.61±0.14 
NMT 6 
4 Terminalia belerica 
4.16±0.07 
NMT 5 
5 Cyperus rotundus 4.25±0.01 NMT 5 
The value are expressed as mean ± SD, (n=3); NMT-Not more than 
 
 
DETERMINATION  OF  ASH  VALUES 
TOTAL ASH  CONTENT 
Total ash content of raw materials was determined, the values obtained and their 
acceptable limits defined are given  table in table.  
Table:11  Total ash value   
S.NO PLANT NAME 
TOTAL ASH 
(% w/w) 
ACCEPTABLE 
LIMITS(w/w %) 
1 Berberis aristata 
4.064±0.12 NMT 14 
2 Terminalia chebula 2.31±0.02 NMT 5 
3 Emblica officinalis 
5.36±2.23 NMT 7 
4 Terminalia belerica 
5.16±0.04 NMT 7 
5 Cyperus rotundus 6.18±0.01 NMT 8 
The value are expressed as mean ± SD, (n=3); NMT-Not more than 
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ACID INSOLUBLE ASH 
 The total ash was used the acid insoluble ash content of individual raw 
materials was determined and results are enumerated in table.  
Table: 12 Acid insoluble ash 
 
S.NO PLANT NAME 
ACIN INSOLUBLE 
ASH(% w/w) 
ACCEPTABLE 
LIMITS(w/w %) 
1 Berberis aristata 
0.34±0.08 NMT5 
2 Terminalia chebula 0.45±0.02 NMT5 
3 Emblica officinalis 
1.17±0.16 NMT2 
4 Terminalia belerica 
0.68±0.01 NMT  1 
5 Cyperus rotundus 2.27±0.04 NMT 4 
The value are expressed as mean ± SD, (n=3); NMT-Not more than 
 
WATER SOLUBLE ASH 
 The total ash content, the water soluble ash content of individual raw 
materials was determined and results are enumerated in table.  
Table: 13  water soluble ash   
S.NO PLANT NAME 
WATER SOLUBLE 
ASH(% w/w) 
ACCEPTABLE 
LIMITS(w/w %) 
1 Berberis aristata 0.78±0.01 NMT 3 
2 Terminalia chebula 
2.31±0.02 
NMT 5 
3 Emblica officinalis 
1.76±0.37 
NMT 3 
4 Terminalia belerica 
2.74±0.59 
NMT 6 
5 Cyperus rotundus 5.73±0.21 NMT 7 
The value are expressed as mean ± SD, (n=3); NMT-Not more than 
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SULPHATED ASH 
 The total ash content, the Sulphated ash ash content of individual raw 
materials was determined and results are enumerated in table. 
Table: 14 Sulphated ash 
 
S.NO PLANT NAME SULPHATED ASH(% w/w) 
1 Berberis aristata 
1.25±0.02 
2 Terminalia chebula 
 
0.12±0.02 
3 Emblica officinalis 
1.5±0.12 
4 Terminalia belerica 
2.2±0.04 
5 Cyperus rotundus 2.8 ±0.12 
The value are expressed as mean ± SD, (n=3) 
 
 
DETERMINATION OF EXTRACTIVE VALUES 
 
Water Soluble Extractive Value 
 Water soluble Extractive values for the raw materials were determined and 
the results are tabulated in table.  
Table:  15 Water soluble Extractive 
 
S.NO PLANT NAME 
WATER  
SOLUBLE 
EXTRACTIVE 
(%w/w) 
ACCEPTABLE 
LIMITS(w/w %) 
1 Berberis aristata 14.29±0.04 NLT 8 
2 Terminalia chebula 61.94±0.17 NLT 60 
3 Emblica officinalis 
51.63±0.20 NLT 50 
4 Terminalia belerica 
2.61±0.69 NLT 35 
5 Cyperus rotundus 12.54±0.15 NLT 11 
The value are expressed as mean ± SD, (n=3); NMT-Not more than 
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ALCOHOL SOLUBLE EXTRACTIVE VALUE 
Alcohol soluble Extractive values for the raw materials were determined (90% 
ethanol) and the results are enumerated in table.  
 
Table: 16 Alcohol soluble extractive   
S.NO PLANT NAME 
ALCOHOL  
SOLUBLE 
EXTRACTIVE 
(%w/w) 
ACCEPTABLE 
LIMITS(w/w %) 
1 Berberis aristata 9.82±0.17 NLT 6 
2 Terminalia chebula 42.66±0.16 NLT 40 
3 Emblica officinalis 
42.36±0.22 NLT 40 
4 Terminalia belerica 
14.88±0.28 NLT 8 
5 Cyperus rotundus 8.08±20 NLT 5  
The value are expressed as mean ± SD, (n=3); NMT-Not more than 
 
ETHER  SOLUBLE EXTRACTIVE VALUE 
 Ether soluble extractive values for the raw materials were determined and the 
results are enumerated in table. 
Table : 17 Ether soluble extractive value 
S. 
 
ETHER  SOLUBLE 
PLANT NAME 
NO EXTRACTIVE(%w/w)  
   
   
1 Berberis aristata 9.28±0.64  
2 Terminalia chebula 8.35±0.42 
  
3 Emblica officinalis 12.68±0.24 
  
4 Terminalia belerica 8.50±0.25 
  
5 Cyperus rotundus 9.25±0.24 
   
The value are expressed as mean ± SD, (n=3) 
 
ANALYSIS OF HEAVY METAL 
 Estimation of heavy metals in the raw materials were carried out and the 
results were recorded and detailed in table. 
 
 
 
 
 Results and Discussion 
Department of Pharmacognosy, MMC, Chennai-03 Page 84 
 
Table: 18 Test for heavy metals 
S.NO PLANT NAME 
OBSERVATION (in ppm) 
Arsenic 
(NMT 
5) 
Lead 
(NMT 
10) 
Cadmium 
(NMT 
0.3) 
Mercury 
(NMT 
0.5) 
1 Berberis aristata 0.002 0.001 0.024 0.004 
2 Terminalia chebula 0.004 0.003 0.005 0.002 
3 Emblica officinalis 0.002 0.004 0.001 0.001 
4 Terminalia belerica 0.001 0.005 0.04 0.04 
5 Cyperus rotundus 0.005 0.002 0.002 0.004 
 The estimation of heavy metals in the sample revealed heavy metals are 
within the prescribed limits. It is safe and does not cause any harm on consumption. 
MICROBIAL LOAD ANALYSIS 
Table: 19 Microbial load analysis 
S. 
No
. 
 
Parameters 
Berber
is 
aristat
a 
Terminal
ia 
chebula 
Emblica 
officinal
is 
Terminal
ia 
belerica 
Cyperu
s 
rotund
us 
1 Total aerobic 
count(NMT 
1000cfu/g) 
Nil Nil 100 100 Nil 
2 Yeast and mould 
count 
(NMT 100cfu/g) 
Nil Nil Nil Nil Nil 
3 E.coli (To be 
absent) 
Absent Absent Absent Absent Absent 
4 Salmonella (To 
be absent) 
 
Absent 
Absent Absent Absent Absent 
5 Pseudomonas(T
o be absent) 
Absent Absent Absent Absent Absent 
6 Staphylocoucus(
To be absent) 
Absent Absent Absent Absent Absent 
 
7 
Shigella (To be 
absent) 
Absent Absent Absent Absent Absent 
 
From the results, it is shown that the powdered raw materials complies with 
the WHO standards for Microbial load analysis and hence it is safer to be taken 
internally. 
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PREPARATION OF EXTRACTS 
 The shade dried crude dried drugs of Berberis aristata (dried Stem), 
Terminalia chebula (pericarp of matured fruit), Emblica officinalis (pericarp of dried 
matured fruit),Terminalia belerica (pericarp of dried ripe fruit) and Cyperus 
rotundus (dried rhizome) weres extracted in soxhlet extractor with ethanol . All the 
extracts were concentrated using rotary vacuum evaporator. The percentage yield 
was calculated for every extract in terms of dried weight of plant material. The 
colour and consistency of the concentrated extracts are given in table. 
 
Table. 20 Percentage yield of various extracts 
S. no 
Plant 
name 
Method of 
extraction 
Physical 
nature 
Colour 
Yield 
%w/w 
1 Berberis 
aristata 
Continuous 
hot 
percolation 
Semi solid 
Dark 
brown 
5.29 
2 Terminalia 
chebula 
22.05 
3 Emblica 
officinalis 
16.9 
4 Terminalia 
belerica 
16.16 
5 Cyperus 
rotundus 
8.75 
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PHYTOCHEMICAL ANALYSIS 
 The chemical tests for various Phytoconstituents in the raw materials were 
carried out and the results were recorded and detailed in table. 
Table: 21 Phytochemical analysis 
 
Phytoc-constituents 
 
Berberis 
aristata 
Terminalia 
chebula 
Emblica 
officinalis 
Terminalia 
belerica 
Cyperus 
rotundus 
Phenolic compounds _ + + + + 
Flavanoids + + + + + 
Tannins _ + + + + 
Alkaloids + + + _ + 
Steroids + + + _ _ 
Glycosides + + + + + 
Saponins + + _ + + 
Proteins + + + + + 
Carbohydrates + + + + + 
Terpenoids + + _ + _ 
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FLUORESCENCE ANALYSIS 
 
Table 22:  Fluorescence analysis of raw materials 
 
SAMPLE 
BEFORE 
TREATMENT 
AFTER TREATING  WITH   50 
%HCL 
AFTER TREATING WITH   50% 
NAOH 
Ordinary 
Light 
Short 
UV 
Long UV 
Ordinary 
Light 
Short UV 
Long 
UV 
Ordinary 
light 
Short UV Long UV 
Berberis aristata Light yellow Black Black Brown Brown Brown Black Black Dark brown 
Terminalia chebula Light yellow Brown 
Dark 
brown 
Light brown 
Brownish 
Green 
Dark 
brown 
Light brown 
Greenish 
brown 
Dark brown 
Emblica officinalis Dark brown 
Light 
brown 
Black Brown Black 
Dark 
brown 
Light brown Black Black 
Terminalia belerica Dark brown Brown Brown Brown 
Brownish 
Black 
Dark 
brown 
Light brown Brown Dark brown 
Cyperus rotundus Black Black 
Light 
brown 
Brown Brown 
Dark 
brown 
Light brown Dull brown Light brown 
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CHROMATOGRAPHIC ANALYSIS 
 The chromatographic analysis for each individual ethanolic extract and 
polyherbal formulation was performed and the results were given in the table. 
 
Figure:Thin layer chromatograpy of individual extract and PHF 
CR- Cyoerus rotundus, TB- Terminalia belerica, TC- Terminalia chebula,  
BA - Berberis aristata, EO - Emblica officinalis, ET - Poly herbal formulation 
PHF - POLYHERBAL FORMULATION  
Table 23: Thin Layer Chromatography Rf values of the extracts 
Extract Solvent 
system 
Number 
of spots 
Distance 
travelled 
by the 
solute (cm) 
Distance 
travelled 
by the 
solvent 
(cm) 
Rf value 
(cm) 
Cyperus 
rotundus 
 
 
 
 
 
Butanol: 
Acetic 
acid: 
Aqueous 
(40: 10: 
20) 
4 2.8; 2.5; 
1.4; 0.5  
3 0.93; 0.83; 
0.46; 0.16 
Terminalia 
belerica 
3 2.5; 1.9; 0.9 3 0.83; 0.63; 
0.3 
Terminalia 
chebula 
4 2.6; 2.2; 
0.9; 0.6  
3 0.86; 0.73; 
0.3; 0.2 
Berberis 
aristata 
6 2.6; 1.8; 
1.5; 1.2; 
1.0; 0.5 
3 0.86; 0.6; 
0.5; 0.4; 
0.33; 0.16 
Emblica 
officinalis 
6 2.6; 2.5; 
2.0; 1.5; 
1.0; 0.5 
3 0.86; 0.83; 
0.66; 0.5; 
0.33; 0.16 
ET (Polyherbal 
formulation) 
6 2.6; 2.4; 
2.2; 1.4; 
1.0; 0.5 
3 0.86; 0.8; 
0.73; 0.46; 
0.33; 0.16 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
 HPTLC was performed for the  ethanolic extraction of polyherbal 
formulation. The chromatographic conditions were carried was detailed in materials 
of  this  study. There were six peaks observed with different Rf values.   
Mobile Phase : Butanol-Acetic Acid-Water (4:1:5). 
 
 
ET- polyherbal extract powder, Std -Flavanoid 
 
HPTLC FINGER PRINTING OF THE POLYHERBAL EXTRACT 
 
 
Fig23: HPTLC of finger print data 
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Table 24: HPTLC finger printing spectral values 
 
Peak Rf value Assigned substance 
        1 0.05 Unknown 
2 0.31 Unknown 
3 0.48 Unknown 
4 0.59 Unknown 
5 0.78 Unknown 
6 0.97 Standard  
 
 The HPTLC finger printing of the polyherbal ethanolic extracts showed the 
above tabulated Rf values with corresponding peak area. 
 HPTLC fingerprint is one of the versatile tools for qualitative and quantitative 
analysis of active constituents of multicomponent sample and also a diagnostic 
method to find out the adulterants to check purity. 
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PREFORMULATION STUDIES 
 Totally four trials of formulation were carried out using different choices of 
excipients considering different facts of manufacturing problems as well as quality 
defects in mind. All the resultant formulations were evaluated for their flow 
property, uniformity of filling, uniformity of weight, moisture content and 
disintegration time.  
Table 25 :Evaluation of trial batches 
Parameters Trial 1 Trial 2 Trial 3 Trial 4 
Bulk density (g/cm
2)
 
0.50±0.04 0.60±0.05 0.55±0.01 0.54±0.04 
Tapped 
density(g/cm
2)
 
0.61±0.02 0.53±0.03 0.54±0.03 0.57±0.04 
Compressibility 
index (%w/w) 
09.99±0.03 09.09±0.63 5.55±0.91 4.71±0.04 
Hausner's Ratio 1.35±0.02 1.43±0.02 1.13±0.12 1.03±0.12 
Angle of repose 
(degrees) 
35.05±1.0 34.66±0.02 43.03±3.78 33.03±3.78 
The value are expressed as mean ± SD, (n=5); NMT-Not more than 
 As per the standards, the flow property of the blend to be filled in the capsule 
should be in good range and was confirmed by the above parameters. Trail batch IV 
showed excellent flow characters and batch IV was taken for capsule filling. 
Table 26: Evaluation Of Inprocess Parameters 
 
PARAMETER TRAIL I TRAIL II TRAIL III TRAIL IV 
     
Flow property Poor flow Poor flow Fair Good 
     
Uniformity of Filling - - Uniform Uniform 
     
Uniformity of Weight - - Less weight Uniform 
     
Moisture content - - 
Within the Within the 
Limit limit    
Disintegration time - - 
Within the Within the 
Limit limit     
 
The trial IV flow properties were Excellent and all parameter were within the 
Specified limits. So, fourth trial was chosen for further studies 
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STANDARDISATION OF THE FINISHED PRODUCT 
 The final formulation was analyzed for its quality control parameters in three 
trials. The mean value was obtained and Standard deviation was calculated. 
Wherever there were no official standard, limits for each parameter was established 
based on trial and error analysis of Trial IV batch capsules. 
EVALUATION OF CAPSULES 
1. Description 
“Light brown ” coloured granules packed in “0” size blue capsules. The 
polyherbal capsules were evaluated for organoleptic characters which include 
colour, odour, taste and nature. 
Table 27. Organoleptic Characters 
S.NO PARAMETER OBSERVATION 
1. Description Light brown granule in blue cap and body "0" size 
capsule 
2. Colour Light brown granule 
3. Odour Characteristic odour 
4. Taste Bitter tate 
 
Table 28. Physical Parameters 
S.NO PARAMETER OBSERVATION 
1. pH (1% aqueous solution) 7.33 ± 0.21 
2. Moisture content 3.98 ± 0.5%w/w 
3. Uniformity of weight 519.3 ±3.4mg 
4. Disintegration time 2’ 32secs ± 0.34 
Results  are reported as Mean ± Standard deviation. 
 
 1% aqueous solution of polyherbal formulation showed neutral pH. 
 The average weight of the capsules was calculated as per I.P and the obtained 
value was within the limit (±7.5%). 
 Disintegration time of the polyherbal capsule was performed as per IP and the 
obtained value showed that the capsule will be disintegrated with in the 
prescribed time for the absorption 
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Table 29. Physicochemical Parameters Of Capsule 
 
S.NO PARAMETERS OBSERVATIONS (%w/w) 
1. Total ash 3.22 ± 0.33 
2. Acid insoluble ash 3.09± 0.46 
3. Sulphated ash 1.63 ± 0.24 
4. Water soluble extractive 5.4 ± 0.53 
5. Ethanol  soluble extractive 1.16 ± 0.11 
6. Ether soluble extractive 1.21 ± 0.24 
 
Results are reported as Mean ± Standard deviation. 
 
PHYTOCHEMICAL ANALYSIS 
 
PRELIMINARY PHYTOCHEMICAL SCREENING OF CAPSULE 
 
Table 30: Preliminary phytochemical screening for polyherbal formualtion 
 
S. No 
Phytoc-constituents 
 
Observation 
1 Phenolic compounds + 
2 Flavanoids + 
3 Tannins + 
4 Alkaloids + 
5 Steroids + 
6 Glycosides + 
7 Saponins + 
8 Proteins + 
9 Carbohydrates + 
10 Terpenoids + 
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QUANTITATIVE ESTIMATION OF PHYTOCONSTITUENT 
 The Polyherbal formulation was found to contain various phytochemical 
constituents and hence it is desirable to quantify few of them in order to establish a 
standard to maintain its quality. Among them the estimation of total phenolics, 
Flavanoids, and Tannin content in the ethanolic extract were decided to be taken as 
parameters. Samples were drawn from three random samples of polyherbal capsules 
and the total Phenolics, Flavonoids, and Tannin content present in them were 
estimated. 
TOTAL PHENOLIC CONTENT 
Table:31 Total Phenolic content 
S.NO 
Concentration of 
 standard 
solution(μg) 
ABSORBANCE 
(765nm) 
1 2 0.016 
2 4 0.028 
3 6 0.038 
4 8 0.052 
5 10 0.063 
6 PHF 0.058 
 
 
Fig 24: Calibration curve of Phenoilc conent 
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 Comparison of standard (Gallic acid) absorbance at various concentration (2 
μg to10 μg) and polyherbal formulation. Sample absorbance corresponds at standard 
absorbance at a concentration of 9μg. Hence the amount of flavanoid s present in 
formulation found to be 9μg. 
 
TOTAL TANNIN CONTENT 
Table:32 Total tannin content 
S.NO 
Concentration of 
  solution(μg) 
ABSORBANCE 
(510nm) 
1 0 0 
2 5 0.08 
3 10 0.16 
4 15 0.25 
5 20 0.32 
6 25 0.37 
6 PHF 0.33 
 
  
Fig 25: Calibration curve of total tannin conent 
 Comparison of standard absorbance at various concentration (5 μg to25 
μg) and polyherbal formulation. Sample absorbance corresponds at standard 
absorbance at a concentration of 22μg. Hence the amount of tannin s present in 
formulation found to be 22μg 
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TOTAL FLAVONOID CONTENT 
Table 33: Total flavonoid conent 
S.NO 
Concentration of 
 standard 
solution(μg) 
ABSORBANCE 
(765nm) 
1 20 0.11 
2 40 0.14 
3 60 0.17 
4 80 0.22 
5 100 0.26 
6 PHF 0.17 
 
 
 
 
Fig 26: Calibration curve of total flavanoid conent 
 
 Comparison of standard (Quercertin) absorbance at various concentration (20 
μg to100 μg) and polyherbal formulation. Sample absorbance corresponds at 
standard absorbance at a concentration of 63μg. Hence the amount of flavanoid s 
present in formulation found to be 63 μg 
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 The estimated amounts of phenolics, Flavanoids, and Tannins were 
enumerated in the Table 34. 
Table 34: Quantitative estimation of phytoconstituents 
S.NO PARAMETER OBSERVATION 
(%w/w)   
                  1 Total tannin content 0.54±0.15 
   
2 Total flavonoid content 3.25±0.37 
   
3 Total phenolic content 1.75±0.21 
   
 
Result (n=3) are reported as Mean ± Standard deviation 
 
 From the results obtained it is determined that the average content of 
phenolics, Flavonoids and Tannins were present in the Polyherbal formulation. 
 
HEAVY METALS ANALYSIS 
 
 Capsules  were  analyzed  for  the  heavy  metals  which  include  Arsenic, 
Cadmium,  Lead  and Mercury. The results are as follows, 
 
Table 35:  Quantitative Heavy metals analysis 
 
S.NO. HEAVY OBSERVATION LIMITS 
 METALS (in ppm) (in ppm) 
1. Arsenic 0.02 5 
    
2. Cadmium 0.02 0.3 
    
3. Lead 0.06 10 
    
5. Mercury 0.01 0.5 
    
  
 
From the results it is shown that the Polyherbal formulation complies with 
the heavy metals limits of the WHO guidelines and hence it is safe to be taken 
internally. 
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MICROBIAL LOAD ANALYSIS: 
Microbial screening is done for the Polyherbal formulation results obtained were 
detailed in table. 
Table 36: Microbial load analysis 
 
S.NO PARAMETER RESULT Limits as per WHO 
    
1 Total aerobic count 196cfu/g NMT 1000 cfu/g 
    
2 Yeast and Mould 15cfu/g NMT 100 cfu/g 
    
3 E.Coli Absent Should be absent 
    
4 Salmonella Absent Should be absent 
    
5 Pseudomonas Absent Should be absent 
    
6 Streptococcus Absent Should be absent 
    
7 Shigella Absent Should be absent 
     
 
(Note: cfu – Colony forming units) 
 
From the results, it is shown that the formulation complies with the WHO 
standards for Microbial load analysis and hence it is safer to be taken internally. 
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 PHARMACOLOGICAL STUDIES 
 
INVITRO ANTI-DIABETIC ACTIVITY 
α -Amylase Inhibition Assay  
  
 
STANDARD ACARBOSE 
 
POLYHERBAL FORMULATION 
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Table.37.  In vitro anti – diabetic activity 
 
 
Compounds Concentration Absorbance S-C S-C/S 
%  
inhibition 
IC50 
              
ACARBOSE 50µg 0.193 0.009 0.04663212 4.663212435   
  100µg 0.209 0.025 0.11961722 11.96172249   
  250µg 0.226 0.042 0.18584071 18.5840708 1600.79 
  500µg 0.284 0.1 0.35211268 35.21126761   
  1000µg 0.339 0.155 0.45722714 45.72271386   
              
  Control 0.184         
              
PHF 50µg 0.205 0.021 0.10243902 10.24390244   
 
100µg 0.256 0.072 0.28125 28.125   
 
250µg 0.344 0.16 0.46511628 46.51162791 279.21 
 
500µg 0.528 0.344 0.65151515 65.15151515   
  1000µg 0.816 0.632 0.7745098 77.45098039   
              
  Control 0.184         
 
 
Fig 27: Graphical representation of the α-amylase inhibition assay 
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IN VIVO ANTI-DIABETIC ACTIVITY 
 
ACUTE TOXICITY STUDY 
 
Behavioural and physical observation of polyherbal formulation treated rats 
(2000mg/kg body weight) 
 
Table : 38 Observation of acute toxicity study 
OBSERVATION 30 mins 4 hrs 14 hrs 24 hrs 
Body weight No change No change No change No change 
Preterminal deaths Absent Absent Absent Absent 
Cage side 
observation Normal Normal Normal Normal 
Motor activity Normal Normal Normal Normal 
Convulsions Absent Absent Absent Absent 
Piloerection Absent Absent Absent Absent 
Lacrimation Normal Normal Normal Normal 
Salivation Normal Normal Normal Normal 
Respiration Normal Normal Normal Normal 
Skin color Normal Normal Normal Normal 
Diarrhoea Absent Absent Absent Absent 
Loss of corneal 
reflex Normal Normal Normal Normal 
Loss of pinnal reflex Normal Normal Normal Normal 
Grooming Absent Absent Absent Absent 
Sedation Normal Normal Normal Normal 
Excitation Normal Normal Normal Normal 
Aggression Normal Normal Normal Normal 
 
The results of acute toxicity study are shown in table .There were no morbidity 
 
and mortality observed for polyherbal formulation treated animals upto 2000 mg/kg. 
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INVIVO ANTIDIABETIC ACTIVITY 
 
ANTIDIABETIC EFFECT OF HERBAL FORMULATION IN 
STREPTOZOTOCIN  AND  NICOTIMANIDE  INDUCED  DIABETIC RATS 
The Albino Wistar rats were divided into four different Groups of six animals each 
as follows.  
Group I : Diabetic rats treated with normal saline 
Group II : Diabetic  rats  treated  with  PHF (200 mg/kg) 
Group III : Diabetic rats treated with PHF (400 mg/kg) 
Group IV : Diabetic  rats treated with Glibenclamide  (0.25 mg/kg).  
Table: 39 The effect of polyherbal formulation on fasting blood glucose levels 
(mg/dl) in STZ and NIC induced diabetic rats 
T
re
a
tm
en
t 
Blood glucose level in mg/dl  
Before 
induction 
After induction 
(Initial day) 
7th day 14th day 21st day 28th day 
Diabetic  
control       
78.5±1.60 215.33±2.71 270.11±2.24 302.19±0.73 326.92±1.20 346±1.60 
PHF 200 mg 
/mg/kg  
76.16±1.51 217±2.71*** 200.6±3.38*** 
115.5±1.69*** 
 
99.21±1.52*** 89.21±1.52*** 
PHF 400 
mg/kg       
76.66±0.84 218.33±7.03*** 183.2±2.06*** 
112.21±1.9*** 
 
86.16±1.27*** 78.51±0.83*** 
Glibenclamide 
0.25mg/kg 
74.5±1.58 220±3.65*** 180.73±2.87*** 
100.7±2.01*** 
 
82.83±0.83*** 74.21±0.84*** 
 
PHF: Polyherbal formulation. Values are expressed as mean±SEM (n=6). 
***P<0.001 compared to diabetic control (one way ANOVA followed by Dunnett’s 
t test)  STZ: Streptozotocin; NIC: Nicotimanide 
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Fig 28: Graphical representation for fasting blood glucose level in albino rats  
 
 
 
Table 40: EFFECT OF POLYHERBAL FORMULATION ON PLASMA 
LIPID PROFILE IN EXPERIMENTAL RATS IN EACH GROUP 
 
GROUP 
Lipid profile (mg/dl) 
Triglyceride Total 
cholesterol 
HDL LDL VLDL 
 
Before  
induction of 
diabetes 
 
62.13±0.32 72.14±1.89 31.26±1.80 37.32±1.26 13.20±0.17 
 
Diabetic 
control 
 
161.04±0.63 142.01±0.62 13.23±0.20 92.62±0.17 41.22±0.27 
 
PHF 200 
mg/kg 
 
65.10±0.46*** 80.11±0.52*** 27.64±0.95*** 42.10±0.08*** 15.12±0.77*** 
 
PHF 400 
mg/kg 
 
67.12±1.02*** 78.20±1.06*** 29.10±0.84*** 39.18±0.94*** 14.65±0.47*** 
 
Glienclamide 
( 0.25 
mg/kg) 
 
68.05±0.10*** 77.11±0.44*** 30.47±0.37*** 39.97±1.09*** 14.00±0.18*** 
PHF: Polyherbal formulation. Values are expressed as the mean±SEM (n=6). 
*P<0.05, **P<0.01, ***P<0.001 compared to diabetic control animals (one way 
ANOVA followed by a Dunnett’s t‑test) HDL: High density lipoprotein; LDL: Low 
density lipoprotein; VLDL: Very low density lipoprotein. 
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Fig 29: Graphical representation of plasma lipid profile in albino rats 
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8. SUMMARY AND CONCLUSION 
 Herbal medicines are the oldest form of health care known to mankind. A 
number of traditional herbal medicinal practices have been adopted for the diagnostic 
prevention and treatment of various diseases.  
 Based on the extensive review of literature, five raw materials were selected 
for the formulated as polyherbal capsules and the antidiabetic potency was evaluated 
in animal model. 
 The herbal raw materials were analyzed for identity, quality and purity as per 
the standards prescribed by WHO and Ayurvedic Pharmacopeia of India.  
 The Physiochemical parameters like Loss on drying, ash values and extractive 
values were determined, which will help in preventing variation in quality of the 
drugs. Preliminary phytochemical investigation revealed the presence of various 
phytoconstituents such as alkaloid, steroids, glycosides, Flavonoids, Phenols, 
Tannins, and terpenoid in the raw materials. 
 The safety of the raw materials was analysed by heavy metals and microbial 
screening and the results found within the standard limits given by WHO. 
 The coarse powders of the selected plants were extracted by using ethanol as 
solvent. The ethanolic extracts were dried by freeze drying and used for the 
formulation. 
 TLC for the each individual plant extracts and polyherbal extract was 
performed.  Further HPTLC fingerprinting of the polyherbal formulation was also 
performed and the resultant chromatogram showed the presence of peaks indicating 
different constituents. The chromatogram can be used as an index for the qualitative 
analysis of the formulation. 
   The dried polyherbal extract was optimized for its quality measures 
and its batch consistency by making four different trial batches (Trial I, II, III, IV). 
 The trials were subjected to preformulation parameters to confirm the 
uniformity and quality. The result concludes that the trial IV was excellent in all 
parameters and the values were found within the standard limits and it was used for 
formulate Polyherbal Capsule. 
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 The developed polyherbal capsules were standardized for its Description, 
uniformity of weight, disintegration time, moisture content, pH, Physiochemical 
parameters, and phytochemical studies. 
 Quantitative estimation of phytoconstituents was done for flavonoid, phenols, 
and tannins. 
 The heavy metal analysis and the microbial load was carried out in polyherbal 
formulation as per the WHO Guidelines and found within the limits. 
  In vitro anti-diabetic activity was done by using α-amylase inhibition 
assay method. It possesses significant antidiabetic activity as compared to standard 
Acarbose. 
 Acute toxicity study was carried as per OECD guidelines 423 and the 
polyherbal capsules were found to be safe upto 2000 mg/Kg body weight. The 
developed and standardized polyherbal capsule was evaluated for its therapeutic 
efficacy by in vivo method using Streptozotocin induced diabetes. 
 Fasting blood glucose parameters and lipid profile were analyzed. The 
formulation showed significant effect compared to the normal range before induction 
of diabetes. The polyherformulation at the dose level of 400 mg/kg showed significant 
decrease in blood glucose level on 7
th
 day. 
 The elevated levels of total cholesterol, LDL and triglycerides were also 
reduced and increases HDL level. The phytochemical study showed the presence of 
flavonoids. This may be responsible for the potent anti diabetic activity. 
 Further studies are recommended for stability studies in the formulated 
polyherbal capsules and also clinical trials have to perform in future in Human 
Volunteers.  
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